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Abstract 
 The production of cardiomyocytes (CMs) from induced pluripotent stem cells (iPSCs) 
presents great potential for patient-specific regenerative therapies and cardiotoxicity drug 
evaluation. The successful translation of iPSCs to these fields requires the development of 
robust bioprocesses capable of producing CMs in high quality, quantity and purity. 
Traditional protocols for CM differentiation of iPSCs lack control and robustness and are thus 
inefficient. Furthermore, efficient cryopreservation and hypothermic storage strategies are a 
demand, as cell banking and transport is a prerequisite for clinical and industrial 
applications. The main aim of this thesis was the evaluation of different bioreactor systems 
for the production and purification of miPSC-derived CMs. Novel strategies for CM 
cryopreservation were tested. Also, CMs were used to study the cardioprotective effect of 
antioxidant compounds.  
The wave bioreactor was the most suitable system for CM differentiation, allowing 
high differentiation yields (60 CMs/input of miPSC) and the production of clinically relevant 
numbers of CMs (2.3x109 CMs), simultaneously reducing bioprocess duration when 
compared to stirred tank bioreactors. Produced CMs presented typical structural and 
functional features. Moreover, CryoStorTMCS10 and FBS+10%DMSO (with ROCKi 
pretreatment) revealed to be suitable solutions for cryopreservation of miPSC-derived CMs, 
achieving high cell recoveries after thawing. In addition, HypoThermosol®-FRS enabled 
hypothermic storage of CMs for up to 7 days. Finally, it was shown that CMs derived from 
miPSCs present potential to be used in the development of cardioprotective assays. 
 This work demonstrates the establishment of a fully integrated bioprocess, capable of 
producing high quality miPSC-derived CMs in environmentally controlled bioreactors and 
ensuring efficient cryopreservation and storage of the produced cells. Hopefully, the 
knowledge acquired with this work can be translated to human iPSCs, presenting a relevant 
step forward towards the application of human CMs to clinical and industrial applications, 
such as cardiac regeneration, disease modeling and cardiotoxicity and cardioprotective cell-
based assays.  
 
Key Words: induced Pluripotent Stem Cells (iPSCs); cardiomyocyte differentiation; 3D 
culture; environmentally controlled bioreactors; cryopreservation; cardioprotection cell-
based assays 
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Resumo 
 A produção de cardiomiócitos (CMs) derivados de células estaminais pluripotentes 
induzidas (iPSCs) apresenta grande potencial para terapias regenerativas e avaliação de 
drogas cardiotóxicas. A transferência de iPSCs para estas aplicações necessita do 
desenvolvimento de bioprocessos robustos e capazes de produzir CMs de elevada qualidade, 
quantidade e pureza. Protocolos tradicionais para diferenciação de iPSCs em CMs revelam 
falta de controlo e robustez sendo ineficientes. Além disso, são necessárias estratégias 
eficientes de criopreservação e armazenamento hipotérmico, sendo que a formação de 
bancos de células e transporte é um pré-requisito para aplicações clinicas e industriais. O 
principal objetivo desta tese foi a avaliação de diferentes sistemas de biorreatores para a 
produção e purificação de CMs derivados de miPSCs. Foram avaliadas novas estratégias para 
criopreservação de CMs. Ainda, CMs foram utilizados para estudar o efeito cardioprotector de 
compostos antioxidantes. 
 O biorreator wave foi o sistema mais apropriado para a diferenciação de CMs, 
permitindo elevados rendimentos de diferenciação (60 CMs/miPSCs) e a produção de 
números clinicamente relevantes de CMs (2.3x109 CMs), simultaneamente reduzindo a 
duração do bioprocesso quando comparado a biorreatores de tanque agitado. Os CMs 
produzidos apresentavam estrutura e funcionalidades típicas. Além disso, Cryostor  TMCS10 e 
FBS+10%DMSO (pre-tratado com ROCKi) revelaram ser soluções adequadas para a 
criopreservação de CMs, atingindo recuperações celulares elevadas após descongelamento. 
Ainda, HypoThermosol®FRS permitiu um armazenamento hipotérmico de CMs até 7 dias. 
Por último, foi demonstrado que CMs derivados de miPSCs apresentam potencial para serem 
usados no desenvolvimento de ensaios cardioprotectores.  
 Este trabalho demonstrou o estabelecimento de um bioprocesso integrado, capaz de 
produzir elevadas quantidades de CMs derivados de miPSCs em biorreatores controlados e 
assegurando criopreservação e armazenamento eficazes das células produzidas. 
Esperançosamente, o conhecimento adquirido neste trabalho pode ser transferido para iPSCs 
humanas, sendo um passo relevante para a utilização de CMs humanos para aplicações 
clinicas ou industriais, tais como, regeneração cardíaca, modelos de doenças e ensaios 
celulares de cardiotoxicidade e cardioprotecção. 
 
Palavras-chave: células estaminais pluripotentes induzidas (iPSCs); diferenciação de 
cardiomiócitos; cultura 3D; biorreatores; criopreservação; ensaios celulares de 
cardioprotecção. 
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1. Introduction 
1.1 Stem cell-based therapies for cardiac repair  
 Cardiovascular diseases (CVD) are one of the major causes of death worldwide, 
accounting for 17.3 million deaths per year [1]. In Europe, they are responsible for 47% of all 
deaths issues (Figure 1.1) [2]. In particular, myocardial infarction (MI) results in massive 
cardiac loss, where up to a billion cardiomyocytes (CMs) die resulting in loss of contractility 
and decreased heart function [3]. Upon injury, the adult heart is endowed of some 
endogenous regenerative capacity, provided by resident cardiac stem cells. However this 
endogenous regenerative capacity is limited as fully differentiated cardiomyocytes can no 
longer proliferate and replace degenerated tissue [4]. 
 
Figure 1.1: Causes of death in Europe, 2011 (adapted from [2]). 
 Cardiac repair (replacement, restoration and regeneration) is thus  essential to 
restore heart function following MI [5]. Heart transplantation remains as the only long term 
treatment available, even though limited due to high costs, shortage of donor organs and 
possible immunological rejection [6, 7]. As new therapies are still a need, emerging 
technologies such as cell-based therapies intend to restore heart function by two 
experimental approaches: enhancement of endogenous heart regeneration [8] and 
transplantation of exogenous cells to repopulate the heart [9]. Notably, combining both 
strategies would certainly provide a better alternative for therapies aiming at restoring heart 
function [3]. 
 Many cell types have been examined as potential cell sources for cell therapy such as 
endothelial progenitor cells, cardiac progenitor cells, mesenchymal stem cells derived from 
bone marrow and pluripotent stem cells (PSCs) (reviewed in [10]). The majority of stem cell 
therapies in cardiac disease involve bone-marrow derived cells. Currently, companies such as 
Cardiovascular diseases 47% 
Cancer 21% 
Respiratory diseases 6.5% 
Injuries and poisoning 7% 
All other causes 20% 
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Baxter, Cardio3 Biosciences or Mesoblast are using this cell source in advanced stages of 
clinical trials (phase 3) [11]. Most candidate cell types improve ventricular function, however 
show limited or no potential to produce cardiomyocytes [4]. The ideal cell source for heart 
transplantation would be a proliferative cell with potential to generate all the different cells 
of the heart [3]. PSCs meet these standards, proliferate indefinitely and differentiate into all 
cell types of the body (except for extra-embryonic tissues), thus being a potential candidate 
for stem cell therapies in cardiac repair [3]. 
1.1.1  Pluripotent stem cells: ESCs vs iPSCs 
 Murine embryonic stem cells (ESCs) were first isolated in 1981 [12] and their human 
counterparts were derived by Thomson in 1998 [13]. ESCs were isolated from the inner cell 
mass of blastocysts, pre-implanted embryos at day 5 of embryonic development (Figure 1.2). 
Blastocysts comprise an outer layer of cells (trophoectoderm) and an inner cell mass. ESCs 
are derived by removing the outer layer and isolating the inner cell mass [14].  
 ESCs can give rise to all cell types of the body, i.e. all three germ layers: endoderm, 
ectoderm and mesoderm, and are thus called pluripotent. These cells present high self-
renewal capacity as they can proliferate continuously giving rise to undifferentiated cells 
[15]. ESCs were the first stem cell source that could reliably give rise to cardiomyocytes in 
vitro (reviewed in [4]). Despite their enormous potential for cell-based therapies, ESCs are 
inevitably associated with ethical considerations due to the manipulation of embryos, are 
technically difficult to derive and still present limitations for clinical applications, such as 
immune rejection and possible teratoma formation (cell tumor containing tissue components 
of the three germ layers)  (reviewed in [3]).  
 Cell differentiation was recently shown to be a dynamic reversible process. In 2006, 
Yamanaka and co-workers were able to reprogram mature cells to a pluripotent state [16]. 
The reverted cells were called induced pluripotent stem cells (iPSCs) and are generated by 
reversing somatic cells to a state of pluripotency (embryonic-like state) by the induced 
expression of specific reprogramming factors [17]. This insight has influenced all areas of 
medicine and physiology, and was awarded the Nobel Prize in Physiology or Medicine in 
2012 (to Dr. John B. Gurdon and Dr. Shinya Yamanaka) for the discovery that mature, 
differentiated cells can be reprogrammed to a pluripotent stem cell state. 
 As mentioned above, the first study on derivation of iPSCs from murine fibroblast was 
reported by Takahashi and Yamanaka in 2006, [16]. In this study, 4 transcription factors (Oct-
4, Sox2, Klf4 and c-Myc) were stated as being the minimal required for maintenance of 
pluripotency  and capable of yielding cells with characteristics similar to ESCs. After iPSC 
formation, reprogramming factors are usually inactivated. Occasional reactivation of specific 
1. Introduction 
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factors can give rise to tumor formation after transplantation [18]. Therefore, in a later study 
reported by Thomson and co-workers, c-Myc and Klf4, well known proto-oncogenes, were 
replaced by Nanog and Lin28 [19]. It has also been shown that combinations of all these 6 
factors are also able to generate iPSCs [7, 19]. 
 
Figure 1.2: Stem cell sources, pluripotency potential and generation of iPSCs. ESCs are isolated 
from early embryos obtained by in vitro fertilization or nuclear transfer, and generating more 
specialized cells (pink arrows). Reprogramming technologies allow generation of iPSCs from mature 
cells, or lineage conversion between differentiated cell types (black arrows). Stem cells and their 
differentiated progeny are used in a variety of applications, such as disease modeling, drug discovery, 
and regenerative medicine [20].  
Bioprocess engineering of induced pluripotent stem cells for applications in cell therapy and pre-clinical research 
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 The first reprogramming protocols relied on the use of integrating vectors to deliver 
desired transgenes into the genome of somatic cells. These integrating vectors were mainly 
retroviral or lentiviral [21, 22]. Even though reprogramming was possible, random transgene 
insertion could interrupt existing genes causing tumor formation (after transplantation) and 
disturb the maintenance of the cells undifferentiated state. This approach presents other 
drawbacks such as low stability, difficult cellular targeting and possible insertion of 
mutagenesis [23]. To overcome these limitations and establish safer iPSC lines, - methods 
that allow the expression of pluripotency genes without integrating host genome are 
currently being explored. For example, non-integrated virus (e.g. adenoviruses, 
baculoviruses)  have been used, despite suffering from low efficiencies [21]. Virus-free 
reprogramming can also be achieved by using episomal vectors or excisable transposon 
systems (e.g. PiggyBac or Cre/loxP systems), which integrate the cells but can be removed by 
transposase, without leaving genetic material behind (reviewed in [21, 24]). Other techniques 
for the generation of safer iPSC lines include the use of exogenous plasmids, protein factors, 
small molecules and microRNAs. Nuclear reprogramming has been shown to be an inefficient 
process. However, a novel method for reprogramming is able to successfully revert cells to a 
pluripotent state, by deleting the Mbd3 gene, which is an important epigenetic regulator that 
restricts expression of pluripotency genes. This method shows reprogramming efficiencies 
near 100% for mouse and human cells [25]. 
 In the last few years, iPSCs are boosting the field of regenerative medicine, offering 
numerous advantages over adult stem cells and ESCs [3]. iPSCs can circumvent the need for 
embryo use, being ethically less controversial, and thereby could potentially replace ESCs. 
Also, differentiated cells derived from iPSCs have recently been shown to present limited 
immunogenicity and could therefore be used in autologous [26] (patient specific) or 
allogeneic therapies (universal donor-derived cells). iPSC-derived cardiomyocytes have 
tremendous potential to be used in cardiac repair strategies. 
 Although recent approaches have proved promising, there are still challenges to 
overcome in order to transfer PSCs to clinical applications. Selection of the adequate cell 
source is crucial, namely whether to use autologous or allogenic therapies. Quantity and 
purity of cells are essential for successful therapies, minimizing tumorigenic potential of 
transplantation. Also, quality is a requirement, assuring the desired phenotype and potency 
of the chosen cell source (reviewed in [15]). 
 Table 1.1 summarizes the major challenges and solutions facing the use of iPSCs in 
cardiac repair. 
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Table 1.1: Major challenges and potential solutions facing the use of iPSCs for cardiac repair 
(adapted from [4])  
Hurdles Possible solutions 
Heterogeneous population of differentiated cells 
- Directed cardiac differentiation 
- Specific selection of cardiomyocytes 
Low cardiomyocyte yield 
- Directed cardiac differentiation 
- Upscaling differentiation process 
Survival, integration and maturation of cell-grafs in vivo 
- Cell delivery approaches 
- Tissue engineering strategies 
- Genetic modifications 
Tumorigenic potential 
- Integration-free iPSCs generation 
- c-Myc-free reprogramming strategies 
- Appropriate selection process 
Risk of genetic modifications 
- Genetic screening of undifferentiated 
iPSCs 
1.2 Cardiomyocyte differentiation 
1.2.1  Understanding cardiac differentiation 
 Cardiomyocyte differentiation of stem cells recapitulates aspects of cardiogenesis in 
vivo, which involves complex processes highly controlled by positive and negative molecular 
signals that guide stem cells towards cardiac fate [27]. As molecular mechanisms in human 
cardiogenesis are still not thoroughly known, cardiac development in animal models (e.g. 
mouse) has provided valuable information to improve in vitro cardiomyocyte differentiation 
protocols (reviewed in [28]). Understanding how the cardiac lineage is established in these 
models is crucial for developing efficient differentiation protocols. Cardiomyocyte 
differentiation of murine iPSCs (miPSCs) was first described by Mauritz et al. [29] who 
utilized the embryoid body (EB) system to obtain cardiomyocytes. 
 The mammalian heart is the first organ developed in embryogenesis and consists of 
three mesodermal cell types: endothelial cells, vascular smooth muscle cells and 
cardiomyocytes [30]. Cardiomyogenesis consists of four consecutive steps: i) mesoderm 
formation, ii) mesoderm patterning toward anterior mesoderm or cardiogenic mesoderm, iii) 
cardiac mesoderm formation and iv) cardiomyocyte maturation [31]. Cardiac development is 
a dynamic process controlled by sequential expression of multiple signal transduction 
proteins and transcription factors. Major signaling pathways have been implicated with 
cardiac subtypes development, such as wingless/INT (WNTs) [32], nodal ([33]), bone 
morphogenic proteins (BMPs) [34] and fibroblast growth factors (FGFs) [35]. During 
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gastrulation (formation of gastrula in early embryonic development) signals mediated 
through WNT/β-catenin and transcription growth factor β (TGF-β) family members promote 
differentiation of ESCs into mesoderm (reviewed in [36]). However, following mesodermal 
induction, WNT/β-catenin signaling inhibits cardiac differentiation and may redirect cells to 
alternate mesodermal fates. This signaling pathway has a biphasic role during cardiac 
differentiation in mouse ECS, being procardiac prior to primitive streak formation and 
presenting an antagonizing role thereafter (reviewed in [36]). Due to this biphasic effect 
during cardiac differentiation, the timing of the addition of specific cardiac factors is crucial 
and must be carefully optimized in order to efficiently drive PSCs to a cardiac cell fate. Figure 
1.3 presents a schematic overview of the steps required for obtaining PSC-derived 
cardiomyocytes and typical markers expressed in each phase. 
 
Figure 1.3: Schematic representation depicting sequential steps required for obtaining PSC-
derived cardiomyocytes. Early mesoderm differentiates via cardiac mesoderm and committed 
cardiac progenitors to functional beating cardiomyocytes. Typical markers for each step are also 
indicated [37].  
 Currently, the main approaches for cardiomyocyte differentiation of PSCs are 
spontaneous differentiation through embryoid body (EB) formation, co-culture with cells 
presenting cardiac inductive activity and guided differentiation strategies (induced by 
environmental factors) (reviewed in [3]). Figure 1.4 presents a schematic overview of current 
differentiation methods used for generating PSC-derived cardiomyocytes. 
 Monolayers-based methods are the simplest approach for cardiomyocyte 
differentiation. PSCs are plated on an extracellular matrix (ECM) or on a top of a monolayer of 
feeder cells. These methods are focused primarily on the timing of application and 
concentration of specific cardiac inductive growth factors (e.g. activin A and BMP4) 
(reviewed in [3]). Other monolayer-based methods have focused on overlaying PSCs with 
hydrogels or specific matrices [38],  also called the matrix sandwich method. When combined 
with sequential application of growth factors, this approach has been reported to generate 
cardiomyocytes with high purity (up to 98%) [38]. Despite the increased efficiency of these 
protocols, cell-cell interactions in EBs can stimulate the expression of early cardiac markers 
(reviewed in [39]), which favors the use of 3D structures for cardiac differentiation, as 
described in the following section. 
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Figure 1.4: Current methods for cardiac differentiation of human PSCs. The 3 major approaches 
for differentiation of PSCs to cardiomyocytes are summarized: Embryoid bodies, monolayer cultures 
and inductive co-culture. StemPro34, APEL, DMEM/F12, KO-DMEM and RPMI/B27 are abbreviations 
of common culture medium formulations used for human PSC cultivation [40].  
1.2.2  Embryoid body formation 
 When cultivated in non-adherent conditions (e.g. hanging drops, ultra low adherence 
culture plates) cells assembled into spheroids, capable of differentiating into derivatives of all 
three germ layers [41]. These three-dimensional (3D) aggregates are called embryoid bodies 
(EBs), because of their ability to recapitulate the early events of embryogenesis [42, 43]. EBs 
can spontaneously differentiate into contracting cardiomyocytes [44]. Early studies identified 
critical culture parameters to optimize in vitro cardiogenesis such as cell inoculum 
concentration, culture medium formulation (addition of serum or growth factors), culture 
strategy and time [45]. Spontaneous differentiation of PSC-derived cardiomyocytes in EBs is 
also highly dependent on cell line and is rather inefficient, usually yielding 10% of 
cardiomyocytes exhibiting beating areas [41, 46]. Regardless of these issues, this method is 
widely used for being simple and cost-effective [21]. 
 Recent studies have shown that aggregate heterogeneity leads to adverse effects on 
differentiation efficiency and reproducibility [47]. To overcome this limitation, forced 
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aggregation methods have been one of the most used strategies to control EB formation and 
size. In this method, defined numbers of PSCs are centrifugated into U- or V-bottomed wells 
(Figure 1.4), leading to the formation of aggregates (also called spin EBs) with the same size 
in each well. Varying the number of cells per well allows the control of aggregate size with 
precision [48, 49]. This method is practical, reproducible and efficient. Engineered microwells 
(Figure 1.4) have also been used to form size-uniform EBs. It involves the microfabrication of 
microwells with defined sizes that are coated with an extracellular matrix, such as Matrigel, 
where cells attach and grow to fill the microwells. Removal of cell colonies from microwells 
results in cell aggregates (also called Microwell EBs) with defined sizes [50, 51]. However, 
microwells present reduced potential for scaling-up, requires appropriate and specialized 
technology and are currently not commercially available (reviewed in [40]). An alternative 
engineering approach is the use of micropatterned surfaces (Figure 1.4). In this approach, 
cells are cultivated on a micropatterned ECM (e.g. Matrigel) islands. Size of the colonies can 
be controlled by varying the size of these islands (e.g. 200μM, 400μM and 800μM) [47, 52]. 
Size-controlled EBs (Micropattern EBs) can be achieved after mechanical dissociation of 
colonies. Protocols for spontaneous differentiation of PSC via EB formation have been 
optimized aiming at improving cardiomyocyte differentiation yields, by adding specific 
growth factors in combination with defined medium formulations [40]. 
1.2.3  Co-culture of PSCs with END2 cells 
 Another method for cardiomyocyte differentiation of stem cells is the co-culture of 
PSCs with a visceral endoderm-like cell line (END-2) derived from mouse P19 embryonal 
carcinoma cells [53]. This method was developed based on the discovery of cardiac inductive 
activity of endoderm in early embryonic studies (reviewed in [54]). The inductive effect of 
END-2 cells is not dependent on cell-cell contact, as studies have shown that conditioned 
media derived from END-2 culture is sufficient to induce cardiac differentiation of human 
ESCs (>10% cardiomyocytes) [55]. The presence of END-2 cells in culture causes rapid 
depletion of insulin, a common media supplement that inhibits cardiogenesis [56]. END-2 
cells also produce significantly higher levels of prostaglandin I2 (PGI2), a  lipid molecule that 
enhances cardiac induction [56]. Co-culture of PSCs with END-2 cells is a simple and rapid 
protocol to differentiate hPSC into cardiomyocytes, as it requires few cells and generates 
cardiomyocytes in sufficient quantity and quality to detect visible beating areas and identify 
sarcomere structures [40]. Despite being a protocol with very low differentiation efficiency 
(5-20% cardiomyocytes), optimization with serum- and insulin- free protocols results in 
higher differentiation efficiencies [55].  
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1.2.4  Guided differentiation with growth factors and small molecules 
 Many growth factors are used to enhance mesoderm formation and cardiomyogenesis 
in cultures of PSC, as described above (Section 1.2.1). BMPs, members of the TGF-β family, 
play a key role in promoting mesoderm formation and specifying myocardial lineage 
commitment during differentiation [57, 58]. Activin A, also a member of TGF-β, has been 
demonstrated to promote cardiomyogenesis in PSCs (reviewed in [57]). It has been shown 
that sequential addition of these two growth factors (at specific concentrations) can generate 
spontaneous contracting areas within 10 days and 30% of differentiated cardiomyocytes 
within three weeks, under feeder-free and serum-free culture conditions [59]. The WNT 
family, specially the WNT/β-catenin pathway, has stage dependent effects on cardiac 
differentiation. Activation of this pathway at the beginning of differentiation (prior to 
gastrulation) enhances cardiomyogenesis, but in later stages, after mesoderm formation, 
inhibitory effects of cardiomyogenesis are observed [60]. FGFs have also been described to 
influence survival and proliferation of cardiac precursors [27]. More specifically, FGFs 
cooperate with BMPs to further induce cardiomyogenesis; this cooperation was 
demonstrated in chick embryos, as FGF2 and FGF4 induce cardiomyogenesis in non-
precardiac mesoderm, but differentiation is more efficient in the presence of BMP2 or BMP4 
[61]. Efficient cardiomyocyte differentiation has also been verified when combining different 
types of growth factors added into culture medium at specific time points [54]. As an 
example, it was shown that the sequential addition of activin A, BMP4, basic fibroblast growth 
factor (bFGF), Dickkopf homolog 1 (DKK1) and Vascular Endothelial Growth Factor (VEGF) 
yields 40%-50% of cardiomyocytes [62, 63]. Indeed, guided differentiation protocols, 
through addition of growth factors, usually assure higher yields of cardiomyocyte 
differentiation. However, the high costs associated to the use of growth factors and their low 
stability compromise scalability and reproducibility of differentiation protocols [40].  
 With the advent of high-throughput screening technologies, small molecule libraries 
have been screened to identify molecular interactions leading to a particular stem cell fate 
[40, 54]. The use of small molecules in guided differentiation protocols offer two major 
advantages over growth factors and recombinant protein based methods. First, small 
molecules can diffuse more efficiently throughout multiple cell layers within EBs to modulate 
signaling, thus yielding more consistent results, whereas much larger proteins may not be 
able to access the target cells. Second, a significant advantage of small molecules is that they 
are less expensive than growth factors, offering greater flexibility and scale-up prospects to 
guided differentiation protocols [64]. Several small molecules with potential to enhance 
cardiomyogenesis have been identified (reviewed in [54]). Ascorbic acid, one form of vitamin 
C, has been shown to consistently and robustly enhance differentiation of iPSCs into 
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cardiomyocytes [65]. More specifically, the addition of ascorbic acid at early stages of culture 
(between days 2 and 6) improves by 7.3-fold and 30.2-fold the yields of cardiomyocytes 
derived from mouse and human iPSC, respectively. Ascorbic acid promotes cardiomyocyte 
differentiation by increasing collagen synthesis, enhancing proliferation of cardiac progenitor 
cells and upregulating late stage markers of cardiomyogenesis (e.g. cardiac troponin T, 
sarcomeric myosin heavy chain, α-actinin)  [65, 66]. Moreover, ascorbic acid induced 
cardiomyocytes showed better sarcomeric organization and enhanced responses of action 
potentials and calcium transients during electrophysiological assays when compared to 
cardiomyocytes differentiated in the absence of ascorbic acid. Like ascorbic acid, other small 
molecules like 5-azacytidine (demethylating agent) or cyclosporin-A have been reported to 
possess pro-cardiogenesis effects (reviewed in [54]).    
1.2.5  Guided differentiation promoted by cyclic strains & oxygen 
Stem cell fate is highly dependent on stimuli that lie in the extracellular environment 
that drive specific cellular fates. Substantial effort has been made to identify relevant cues 
governing stem cell fate. As mentioned above (Section 1.2.2-4) cell-cell interactions, the 
extracellular matrix and soluble factors have impact on differentiation of stem cells into 
cardiomyocytes. Stem cell fate can also be influenced by other extrinsic factors such as 
physiochemical environment and physical forces. Since cardiomyocytes are exposed to 
dynamic environments in vivo, these stimuli have potential to further drive differentiation in 
vitro.  
 Physicochemical parameters such as dissolved oxygen concentration have 
tremendous influence on cell cultures. Recent studies have shown that low oxygen tensions 
(2-5%) enhance PSC proliferation [67, 68]. Also, during cardiomyogenesis, many cues and 
processes are influenced by hypoxia conditions [69, 70]. 
 Mechanical stimuli are translated into biological signals that mediate cell structure, 
survival, proliferation and differentiation [71]. Advances in mechanical stimulation have 
shown that fluid shear stress, cyclic strains and magnetically mediated strains present 
potential to drive differentiation of cells that reside in mechanically dynamic environments, 
such as cardiomyocytes [71], vascular smooth muscle cells [72] and endothelial cells [73]. 
Cardiomyocytes in the body are subjected to cyclic mechanical strain induced by the 
rhythmic heart beating [74]. Thus, with the hypothesis that mechanical loading promotes 
cardiomyogenesis of ESCs, a recent study has reported ESCs subjected to mechanical stimuli 
demonstrated commitment towards cardiomyocyte lineage [75]. 
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1.2.6  Scalable production of cardiomyocytes derived from PSCs  
 As mentioned before, PSC-derived cardiomyocytes are powerful cells for cell 
replacement therapies, tissue engineering, drug discovery and in vitro toxicology 
applications. Cell-based therapies may require 108 to 109 hPSCs derived cardiomyocytes per 
patient, reflecting the amount of working myocardial lost in myocardial infarction. Large 
numbers of cardiomyocytes are also needed for drug screening pipelines and in vitro 
toxicology tests (reviewed in [40]). To facilitate the implementation of these cells in clinic and 
industry, there is a need to translate culture protocols developed at research laboratories into 
validated bioprocesses that can guarantee reproducibility, scalability, standardization, 
robustness and safety. The most attractive strategy for manufacturing cardiomyocytes 
derived from PSCs consists in engineering stem cell niches by identifying key factors inducing 
cardiomyocyte differentiation of PSC (as described above – Section 1.2.5) and creating culture 
approaches that allow 3D cell organization in a bioreactor-based system where key 
environmental conditions are finely controlled.  
3D cell culture strategies 
 In the last years, several two-dimensional (2D) monolayer protocols were described 
for the differentiation of PSCs into functional cardiomyocytes (as described above – Section 
1.2.1). However, 2D culture systems inappropriately resemble the in vivo microenvironment, 
mislead in regards to cell-cell or cell-matrix interaction, tissue architecture and biochemical 
signals [15, 76]. These systems also inherit uncontrollability, present low scalability and low 
differentiation yields, making them unattractive and unsuitable for clinical and industrial 
applications [15].  
 Transition from 2D cell monolayers to a 3D cell culturing approach is imperative to 
fully enhance cell performance and potential. 3D culture systems can improve cell viability, 
functionality and also offer higher degree of efficiency, robustness and predictability to 
manufacturing platforms [77–79].  
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Figure 1.5: 2D and 3D strategies for cultivation of PSCs (adapted from [15]). 
 Formation of cell aggregates is one of the most common 3D cell culture strategies 
used in stem cell bioprocessing (Figure 1.5). When cultured as aggregates, cells re-establish 
mutual contacts allowing them to express a tissue-like structure, enhancing cell 
differentiation and functionality [79, 80]. Cell aggregates offer easy handling, scalable and 
reproducible opportunities to process development. The main limitation of this approach is 
the need to control aggregate size, avoiding diffusion gradients inside the aggregate that lead 
to necrotic centers and/or spontaneous differentiation [15]. Cell harvesting is also an issue as 
dissociation of aggregates can compromise cell viability [81]. This approach has been widely 
used for cardiac differentiation [69, 82] 
 One method for controlling cellular aggregation in suspension conditions is the use 
microcarriers (Figure 1.5). A microcarrier is a support matrix that allows the growth of 
anchorage-dependent cells in suspension systems. A wide range of microcarrier types have 
been proposed for the cultivation of PSCs (porous, non-porous, composed by gelatin, glass, 
collagen, cellulose) presenting dimensions within the range of 10–200 μm.   A major 
advantage of microcarrier technology in PSC bioprocessing is the flexibility to easily adjust 
the area available for cell growth, further facilitating the process scale-up. From 
clinical/industrial perspectives, this attribute has a tremendous impact on reducing the costs 
of cell manufacturing (reviewed in [15]). However, this approach presents disadvantages 
such as microcarrier clumping [83] and harmful shear stress effects (cell damage due to 
physical forces). Microcarrier technology has also been used for differentiation towards 
cardiomyocyte lineage [84, 85]. 
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 Cell microencapsulation in hydrogels (Figure 1.5) ensures an environment free of 
shear stress while avoiding cell clumping [83]. The main benefit of cell microencapsulation 
technology is the possibility of designing the scaffold environment with specific biomaterials 
that exhibit a wide range of mechanical/chemical properties, correlating to the properties of 
native tissues. Nonetheless, microencapsulation also presents drawbacks such as additional 
costs associated to the use of hydrogels and other materials, limited gas and mass diffusion 
inside the capsule pores and difficult culture monitoring (reviewed in [15]). Studies have 
shown that PSC-derived cardiomyocytes can be obtained using cell microencapsulation [86] 
Bioreactors for PSCs cultivation 
 One of the most used strategies for scaling-up the production of PSC derivatives 
consists in cultivating cells using dynamic culture systems [40]. Spinner flasks (Figure 1.6A) 
have been widely used for PSCs expansion [83] and differentiation into cardiomyocytes [87]. 
However this culture system lacks culture control over parameters like temperature, pH or 
gas exchanges (e.g. oxygen).  
       
     
Figure 1.6: Examples of different bioreactor designs used for stem cell bioprocessing. A) Spinner 
flask. B) Stirred tank bioreactor [88]. Single-use disposable bioreactors: C) Single-use stirred tank 
bioreactor (Mobius CellReady, Millipore) (www.millipore.com). D) Wave induced bioreactor (WAVE 
Bioreactor, GE Healthcare) [88]. E) Pneumatically mixed bioreactor (PBS 3, PBS Biotech) 
(www.pbsbiotech.com).  
A) 
 
B) 
 
C) 
 
D) 
 
E) 
 
Bioprocess engineering of induced pluripotent stem cells for applications in cell therapy and pre-clinical research 
14 
 
 Bioreactors for PSC bioprocessing should accurately control and regulate cellular 
microenvironment, aiming at supporting cell viability while providing spatial and temporal 
control of signaling. Different bioreactor types have been used for PSC cultivation such as 
microfluidic culture systems, rotatory culture systems and stirred tank bioreactors (reviewed 
in [89]). Stirred tank bioreactors (Figure 1.6B-C) offer efficient gas/nutrient transfer, precise 
control and monitoring of culture environment (e.g. pH, temperature, pO2, gas composition, 
nutrients) and non-destructive sampling (Figure 1.6B-C). These bioreactors offer enormous 
engineering prospects, as they are scalable, reproducible, versatile and fully automated. One 
of the main limitations of stirred tank bioreactors is the hydrodynamic shear stress promoted 
by stirring. Up to now, the minimal volume required to set up the experiments was very high 
(approximately 50 mL), which compromised the use of stirred bioreactors for high-
throughput applications by demanding higher starting cell numbers and increasing the costs 
associated to optimization studies. Large efforts have been made towards the development of 
smaller scale systems (working volume 10–15 mL) and two options are available today 
including the ambr® systems (from TAP Biosystems) and the low volume spinner flasks 
(from HexaScreen).  
 During the last decade, single-use disposable bioreactors have been developed and 
applied in preclinical, clinical, and production-scale biotechnological facilities [90]. In 
contrast to reusable bioreactors made from glass or stainless steel, single-use bioreactors are 
made of FDA-approved (Food and Drug Administration) plastics [91]. Single-use bioreactors 
offer several advantages such as reduced costs in construction of production facilities, 
reduced risk of cross-contamination, less cleaning validation needed and rapid changeover of 
processes [92]. However, these bioreactors also present limitations including lack of 
instrumentation for single-use sensors, possible secretion of leachables and extractables from 
the plastic cover and limited number of vendors available [91, 92].  
 Today, there are different disposable bioreactor types commercially available ([90, 
91]). These include spinner vessels, such as the SuperSpinner D 1000 (Sartorius), and stirred 
tank disposables: Mobius CellReady (Millipore; Figure 1.6C), Univessel SU (Sartorius) and 
CelliGen BLU (Eppendorf); micro bioreactors are also available, the Ambr bioreactor. 
Different bioreactor designs have also been developed as single-use disposables. One 
example is the wave induced bioreactor (WAVE Bioreactor from GE Healthcare and BIOSTAT 
CultiBag from Sartorious-Stedim). This bioreactor (Figure 1.6D) has a rocking platform 
capable of inducing a wave motion in the culture media without an impeller or other invasive 
mixer. This rocking system promotes rapid medium homogeneity and provides the optimal 
oxygen transfer in the inflated bag [92, 93]. Studies has shown that this bioreactor presents 
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lower shear stress when compared to the stirred tank bioreactor [94].  In addition, this 
bioreactor has a simple design, appealing to either biological engineers or medical 
professionals. Pneumatically mixed bioreactors (e.g. Air-Wheel® Bioreactor Systems from 
PBS Biotech (Figure 1.6E)) are another example of disposable devices with unique 
characteristics. This bioreactor provides mixing and optimal oxygen transfer via gas 
buoyancy (air bubbles), eliminating the need for an external mechanical agitator [92, 95]. 
This pneumatic mixing type assures low shear stress [95], always an advantage for stem cell 
bioprocessing.  
 In order to enhance stem cell metabolism and further improve cell viability, 
proliferation and differentiation, different operation modes can be adopted, including fed-
batch and perfusion [15]. The fed-batch strategy is considered the most adequate for 
optimizing cell metabolism, enabling a more efficient uptake and consumption of nutrients, 
resulting in reduced accumulation of metabolites in culture supernatant [96].  Perfusion 
strategies have been developed in stem cell bioprocesses to ensure continuous renewal of 
nutrients and growth factors and constant removal of toxic byproducts [70, 96]. Growth 
factors play an important role in stem cell processes, providing survival, proliferation and 
differentiation signals. This feature of continuous medium addition and removal has potential 
to be integrated in expansion, differentiation and/or cell lineage selection steps. Addition of 
different medium formulations and removal of cell debris are also possible using perfusion 
strategies. 
 Optimization of PSC bioprocessing should result in large cell yields through process 
intensification, specialization and integration, rather than just scale-up technologies [15]. The 
establishment of platforms capable of integrating isolation and reprogramming, inoculation, 
expansion, differentiation, purification and harvesting would result in the scale-up of well 
differentiated cells to clinical relevant numbers [15]. Several bioprocesses combining PSC 
(human and mouse) expansion and cardiomyocyte differentiation have been reported in 
recent years. Table 1.2 presents results of recent studies integrating PSC-derived expansion 
and differentiation in computer controlled bioreactors, operating in batch and perfusion 
modes. 
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Table 1.2: Studies involving cultivation of mESCs in scalable 3D approaches involving expansion and 
differentiation into cardiomyocytes.  
Stirred Tank 
Bioreactor 
Operating 
mode 
Culture 
volume (ml) 
Initial cell 
number 
Final CM 
number 
CM/ESC 
ratio 
Ref 
Standard Spinner vessel Batch 250 5x107 5.86x107 1.2 [97] 
DASGIP Cellferm-Pro 
(DASGIP Tech.) 
Perfusion 250 0.9x106 3.5x106 3.8 [70] 
Biostat MD (Sartorius) Batch 2000 2x108 1.28x109 6.4 [98] 
Biostat MD (Sartorius) Perfusion 2000 2x108 4.6x109 23 [99] 
 
1.3 Purification of iPSC-derived cardiomyocytes 
 The use of cardiomyocytes derived from PSCs in cell-based therapy has been 
hampered by the inability of differentiation protocols to obtain homogenous, pure and 
functional cardiomyocytes. To prevent unwanted side effects, like tumor formation or 
inefficient therapies, it is necessary to eliminate the high degree of heterogeneity of the final 
cell population (reviewed in [3]). Therefore developing effective purification protocols is 
imperative to obtain populations highly enriched in cardiomyocytes. There are several 
purification/enrichment strategies, including genetic and non-genetic approaches for 
selection based on distinct cellular and molecular characteristics of cardiomyocytes. 
1.3.1  Genetic selection of cardiomyocytes 
 Genetic-based purification protocols allow efficient enrichment of cardiomyocytes in 
mESC cultures (purity >99.6% [100]). In this approach, undifferentiated cells are genetically 
modified to integrate and stably express a transgene, such as a fluorescent marker (e.g. eGFP, 
dsRed) or an antibiotic-resistant gene (e.g. resistance against geneticin, puromycin) under 
control of a specific cardiac promoter. A number of cardiac specific promoters have been 
used, such as human myosin light chain ventricular isoform (Myl2) [101] and mouse [102] 
and human [103] cardiac α-myosin heavy chain (α-MHC). Since differentiated 
cardiomyocytes express these selection markers, these cells can be selected from a 
heterogeneous population by fluorescence-activated cell sorting (FACS) or by addition of 
antibiotics, if the transgene encodes antibiotic resistance genes (reviewed in [54]). Although 
this approach results in a highly enriched population, it presents some disadvantages, as 
genetic modification of cells can promote/induce tumor formation, cell lines have to stably 
express the transgene, which is a time consuming process,  and the enrichment process is 
highly dependent on cell line [54].  
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1.3.2  Non-genetic purification of cardiomyocytes 
 Cell lineage purification from heterogeneous populations can also be achieved using 
non-genetic methods. These strategies range from mechanical to biochemical methods, based 
on cells physical and structural properties (reviewed in [3]). 
 Micro dissection and Percoll gradient centrifugation are the most widely used 
methods for cardiomyocyte enrichment [21]. Micro dissection is based on the isolation of 
contracting areas, enriched with cardiomyocytes, through the manual dissection of these 
areas from a cell culture plate [104]. In Percoll separation methods, dissociated cells are 
loaded onto two layers of Percoll and centrifuged, enabling separation of cardiomyocytes 
from non cardiac cells, who will reside in a upper layer (lower density than cardiomyocytes) 
[105]. Both these techniques are simple and inexpensive, however they lack scalability and 
are time-consuming (reviewed in [40, 54]). 
 Enrichment of cardiomyocytes can also be carried out by targeting specific surface 
markers of cardiomyocytes. Using specific antibodies, enrichment is possible by selecting 
differentiated cardiomyocytes (positive selection) or non-cardiac cells (negative selection), 
since their surface marker expression is distinct (reviewed in [54]). Three surface markers 
are associated with stem-cell derived cardiomyocytes:  signal-regulatory protein alpha 
(SIRPA) [106], vascular adhesion molecule 1 (VCAM1) [107] and activated leukocyte cell 
adhesion molecule (ALCAM) CD166, which is a specific marker for early murine 
cardiomyocytes [108]. Cell sorting can be achieved with fluorescence-activated cell sorting 
(FACS) or magnetic-assisted cell separation (MACS) techniques. FACS can simultaneously 
target multiple markers, while MACS can only target a single marker although presenting 
higher throughput. These methods can assure enriched populations, containing over 90% of 
cardiomyocytes [54]. However studies have shown that these approaches result in the loss of 
some cardiomyocytes, as not all express these markers [106, 107]. Cardiomyocytes have a 
unique feature of presenting high content of mitochondria. Thus, labeling the mitochondria of 
cardiomyocytes with fluorescent dyes provides another means of purification. 
Tetramethylrhodamine methyl ester perchlorate (TMRM) has been used for this purpose, as 
it is non-toxic to cells and the labeling is reversible [109]; using this method cardiomyocytes 
can be efficiently selected (99% of purity) using FACS, as they will be part of the high 
fluorescence intensity fraction [3, 109]. 
 Recently, novel purification methods have been developed based on distinct 
metabolic flows of cardiomyocytes. Exploiting distinct metabolic flow methods, studies have 
stated that 99% purity can be achieved using glucose depleted culture medium containing 
abundant lactate, using either mouse or human PSC-derived cardiomyocytes [110, 111]. This 
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cardiomyocytes enrichment protocol is achieved without the use of complex devices or labor-
intensive steps, being adequate for clinical applications [111]. 
1.4 Characterization of cardiomyocytes  
 Structural and functional characterization of differentiated cardiomyocytes is 
essential to evaluate the outcome of differentiated protocols and quality of cell-based 
products. For cell-based therapies, characterization of cell-based product or cells to be used 
in transplantation is important to minimize the risk of host rejection, tumor formation or 
arrhythmias (reviewed in [3]). In the last few years, extensive characterization of PSC-
derived cardiomyocytes have been carried out to evaluate and confirm their cardiac 
phenotype [40, 112]. 
 The cardiomyocyte differentiation process of PSCs can be monitored by following the 
temporal gene expression pattern.  Pluripotency  markers are down-regulated soon after 
differentiation followed by up-regulation of cardiac mesoderm markers and then 
cardiomyocyte-associated genes (reviewed in [54]). To confirm the phenotype of the final 
differentiated population, it is essential to detect the expression of cardiomyocyte-associated 
genes [113]. Some of these cardiac proteins are described in Table 1.3. 
Table 1.3: Cardiac markers used for the characterization of cardiomyocytes (adapted from 
[54]).  
Structural proteins α-Actinin; cTnT; cTnI; α/β-MHC; Myl2; Myl7; Desmin;  Titin 
Transcription factors NKX2-5; GATA4; MEF2C; TBX5; TBX20 
Gap junction proteins N-cadherin; Connexin 43 
Surface proteins and ion channels α1/β1-adrenergic receptors; L-type calcium channel, HCN4 
* cTnT – cardiac troponin T; cTnI – cardiac troponin I; MHC – myosin heavy chain; Myl2/Myl7 – myosin 
light chain (ventricular/atrial); NKX2-5 – NK2 transcription factor related locus 5; Gata4 – Zinc finger 
transcription factor 4; MEF2C – myocyte enhancer factor; TBX5/TBX20 – T box protein 5/20; HCN4 – 
Hyperpolarization Activated Cyclic Nucleotide-Gated Potassium Channel 4. 
 There are some techniques available to ensure a robust and efficient characterization 
of PSC-derived cardiomyocytes. These techniques enable characterization based on the 
morphologic, structural and electrophysiological properties of cardiomyocytes. Flow 
cytometry (Figure 1.7A) provides a quantitative method to evaluate the purity of the 
differentiated and enriched population, by measuring the number of cells expressing cardiac-
specific proteins [3]. Reverse transcription-polymerase chain reaction (RT-PCR, Figure 1.7B) 
can be used to assess changes in gene expression throughout the differentiation process. 
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Studies have also shown that changes in cardiomyocyte gene expression can also be 
characterized with a transcriptional profiling approach, using microarrays analysis [114]. 
Immunofluorescence microscopy (Figure 1.7C) using specific antibodies is another strategy 
used for evaluating structural characterization of cardiomyocytes  [40].  
 Cardiomyocytes can also be characterized based on their functional properties. 
Studies have shown that PSC-derived cardiomyocytes display functional properties of early-
stage human heart cells, including atrial, ventricular and pacemaker phenotypes (reviewed in 
[37]). Functional assays should also demonstrate that cardiomyocytes can generate action 
potentials (APs) when stimulated by an electric signal, resulting in intracellular Ca2+ release 
and, as a consequence, cell/muscle contraction [37, 112]. This characterization is achieved 
using electrophysiology or calcium indicator assays (e.g. Fluo-3, Rhod-3) (Figures 1.7D-F).  
 
Figure 1.7: Basic characterization of PSC-derived cardiomyocytes. A) Flow cytometry provides a 
quantitative method to evaluate relative yield and purity of cardiomyocytes. Measurement of cells 
expressing cardiac troponin T (cTnT). FSC indicates forward scatter; B) Reverse transcription-
polymerase chain reaction is used as a first assessment for changes in gene expression typical of 
cardiogenesis. ES indicates embryonic stem cells, EB embryoid body, H1 and H9 are ESC lines, and LV 
left ventricular cells; C) Immunofluorescence microscopy with antibodies specific for myofilament 
proteins determines whether cells exhibit organized sarcomeres typical of cardiomyocytes. MLC 
indicates myosin light chain. D) Functional assessment of cardiomyocytes can be provided by cellular 
electrophysiology measurements to determine whether cardiac action potentials of different 
cardiomyocyte subtypes are present; E) Extracellular field potential measurements by multielectrode 
arrays provide a method to detect spontaneous electric activity in cardiomyocyte preparations; F) 
Detection of Ca2+ transients typical of cardiomyocytes providing another assessment of functional 
integrity of differentiating cardiomyocytes. Cells loaded with the Ca2+ indicator Fluo-3 were imaged by 
B) 
 
C) 
 
D) 
 
E) 
 
F) 
 
A) 
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laser scanning confocal microscopy in the line-scan mode with Ca2+ transients displayed and time 
versus normalized Ca2+ transient intensity (F/F0) shown below [40].  
1.5 Cryopreservation and storage of PSC-derived cardiomyocytes 
 The therapeutic use of clinical grade cardiomyocytes is also dependent on developing 
efficient, scalable and integrated methods for storage of cardiomyocytes. Several companies 
and academic institutes have aimed at establishing good manufacturing practices compatible 
(GMP), efficient and customized cryopreservation protocols for long term storage of 
cardiomyocytes derived from PSC bioprocessing (reviewed in [115]). Cryopreservation of 
cardiomyocytes is considered a critical step in an integrated bioprocess, since it can exert 
tremendous influence and irreversible effects on cardiomyocyte quality. For successful 
allogeneic therapies, banking and recovery of stored cells must be accomplished without 
compromising cell viability or function, promoting adoption of  cell-based allogeneic products 
(reviewed in [115]). Preserving cells also allows the generation of master and working cell 
banks so that consistent and quality-controlled stocks of cells are available for in vitro 
toxicology studies or drug screening purposes [116]. 
 Cryopreservation-induced events, such as ice crystallization or osmotic shock 
induced-necrosis, activated apoptosis, disruption of cell–cell and cell–matrix adhesions, affect 
survival and fate of stored cells during cryopreservation (reviewed in [115]). Thus, 
developing robust cryopreservation and storage processes that have minimal adverse effects 
on PSC-derived cardiomyocytes is crucial for successful banking and shipping [117]. 
Cryopreservation is defined as the maintenance or storage of biological material at 
temperatures typically below the glass transition of pure water (-132°C), at which biological 
metabolism is dramatically diminished [118]. As differentiation protocols are complex and 
lengthy, preserving stocks of PSCs allows time for quality control and safety testing, ensuring 
the usage of quality and well characterized PSCs, reducing waste and process inefficiency 
[117].  
 Suitable storage strategies at low temperatures (hypothermic storage) are also a 
demand for transport and delivery of cells, for short time periods [117].  Hypothermic 
storage can be defined as the preservation of cells and tissues at chilled temperatures that 
often range between 4 and 10°C. Commercial solutions (e.g. Prime-XVTM Hypothermic 
Preservation Solution, Irvine Science, and HypoThermosol®-FRS, BioLife Solutions Inc.) are 
available for hypothermic storage of cells and tissues, as cryopreservation can be circumvent 
when simple transportation is needed using hypothermic solutions. 
 A cryopreservation procedure involves the steps represented in Figure 1.8. A pre-
freezing treatment is necessary to bring cells to the state at which they will be frozen (e.g. 
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single‐cell suspension, cell aggregates, cell monolayers),. Then cells are transferred to the 
platform where they will be cryopreserved (e.g. cryovials, well-plates). Before the freezing 
process, samples are loaded with cryoprotective agents (CPA; e.g. DMSO, glycerol) to help 
minimize cryoinduced damage during the freezing and thawing procedure. Increased 
attention has been given towards the development of preservation formulations, such as 
Cryostor, STEM-CELLBANKER or Synth-a-Freeze [115]. The cells are then frozen at the 
desired cooling rate to the storage temperature at which they will be stored (e.g. -80°C, -
196°C) Upon cell thawing, CPAs are removed diluting the sample in medium, after which 
post-thaw cell recovery is evaluated [119].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Main steps composing common cryopreservation procedure for mammalian cells. 
Important parameters for each step are listed. 
 Slow-rate freezing is a common approach and is the most appropriate method when 
dealing with large quantities of cells [120].  Slow-rate freezing consists in freezing samples at 
a slow cooling rate to minimize the possibility of intracellular ice formation, which is likely to 
be formed due to the large fraction of water in biological cells and tissues. Slow cooling helps 
prevent ice formation, by promoting cell dehydration during the freezing step. Basic 
principles and damaging events underlining slow cooling injury have been well documented. 
Cells can be damaged due to cryoprotectant toxicity, osmotic damage due to exposure and 
-Cryovessel (e.g. vial, well-plate, freezing bag, straw) 
-Cooling rate (slow-rate freezing versus vitrification) 
-Cooling apparatus (isopropanol-based freezing 
system, programmed rate freezer) 
-Cooling profile 
-Time for assessment of recovery  
-Viability / functionality assays 
-Storage temperature (-80°C, vapor-phase of LN2; -130°C to  
-170°C), LN2 (-196°C)) 
-Cell manipulation (e.g. detachment by enzymatic and/or 
mechanical means, entrapment in polymeric gels)  
-Cell state (e.g. single-cell suspension, adherent cells, cell 
aggregates)  
-CPA (e.g. DMSO, glycerol, trehalose) and cryopreservation 
solution (e.g. serum containing / serum-free medium, commercial 
solutions)  
-Evaluation of cell viability and/or functionality 
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processing 
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-Warming rate (e.g. water bath, CO2 incubator)  
-CPA dilution (single-step versus stepwise dilutions) 
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Evaluation of cell 
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removal of cryoprotectants and high solute concentrations to which cells are sometimes 
exposed during freezing [121]. To avoid cell damage, cells are suspended in specific 
quantities of cryoprotectant agents (e.g. 5-20% DMSO in medium or serum) and placed in a 
controlled rate freezer or in an isopropanol bath, able to cool the sample at 1°C/min. CPAs 
(penetrating and non-penetrating) can protect cells reducing concentration of damaging 
electrolytes, at given subzero temperatures, and reduce the extent of cell volume change 
during the freezing and thawing process [122]. 
 Several protocols for cryopreservation of undifferentiated cells have been reported to 
date [123]. However, there is still a need to develop effective cryopreservation protocols for 
cardiomyocytes derived from PSCs. Recent studies have shown that cryopreservation of 
hESCs-derived cardiomyocytes is possible, cryopreserving cells as a single cell suspension 
and achieving cell recoveries over 80% [124]. Due to the lack of results and information 
regarding PSC-derived cardiomyocyte cryopreservation, novel 2D and 3D cryopreservation 
strategies are a demand for efficient storage after bioprocess production of PSC-derived 
cardiomyocytes.  
1.6 PSC-derived cardiomyocytes as promising cell models for cardiotoxicity 
assays 
 The pharmaceutical industry currently generates large libraries of new drugs with the 
aim of selecting those most promising for clinical trials [125]. Drug attrition rates have 
drastically increased in the past years, resulting in growing costs for the pharmaceutical 
industry and consumers, as drugs often fail during advanced stages of clinical trials [126]. At 
an early stage, to improve drug safety and reduce development costs it is crucial to 
distinguish specific from off-target effects of drugs [125]. In addition to safety and efficacy 
issues, drugs fail due to the lack of in vitro models that correlate with clinical results and poor 
preclinical toxicity screening assays [127]. Recent withdrawals of prescription drugs that 
affect the heart have highlighted the need for more reliable cardiac safety pharmacology 
assays.  
 PSC-derived cardiomyocytes have potential to be considered as a suitable model for in 
vitro assessment of pharmacological and toxicological studies [128]. Cardiomyocytes from 
animals been used for these applications however they are inadequate for this purpose as 
they do not fully translate to results observed in humans and show qualitative differences 
inter-species [129]. Cardiomyocytes differentiated from PSCs have potential to overcome 
these limitations, by reducing the burden of animal model use, decreasing time and cost of 
bringing new drugs to market [127]. These cells also display many characteristics of human 
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cardiomyocytes, including structural, functional and molecular properties making them 
suitable for drug discovery applications, disease modeling and cardiotoxicity screening [127]. 
Oxidative stress and cardioprotection 
 Heart failure and many of the conditions that predispose to heart failure are 
associated with oxidative stress. Several drugs that advance to clinical trials are later 
withdrawn from the market due to cardiotoxicity issues (e.g. Terfenadine, Cisaprine, 
Grepafloxacin) [130]. Also, many anti-cancer drugs tested in clinical trials (e.g. doxorubicin, 
paclitaxel and docetaxel) are associated with the generation of reactive oxygen species (ROS), 
thus leading to oxidative stress and major cell damage [131]. ROS, such as superoxide (O2-), 
hydrogen peroxide (H2O2) or hydroxyl (OH-), are small molecules produced by several 
enzyme systems in cardiomyocytes, either as a primary product or as a secondary byproduct. 
When existent in adequate quantities, ROS are involved in the synthesis of energy and in 
boosting the cells defense mechanism. However, when their production overcomes their 
removal, the cells experience oxidative stress which may cause adverse effects due to 
irreversible modification of macromolecules, causing damage on the cells membranes, 
proteins and DNA [132].  
 Antioxidant compounds (e.g. catechin, resveratrol, procyanidin, polyphenols) have 
been shown to present ROS scavenging properties, resulting in protection against cellular 
damage from oxidative stress [133]. The use of antioxidant compounds has become an 
attractive intervention in attenuating drug-induced cardiomyopathy. Thus, developing 
suitable oxidative stress models of PSC-derived cardiomyocytes is imperative for many drug 
screening, cardiotoxicity and cardioprotection assays. 
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2. Aim of the thesis 
 The main aim of this thesis was the development of a robust, scalable and integrated 
strategy for miPSC-derived CM production and selection. This approach should allow the 
achievement of high CM differentiation yields and CM enrichment at the end of the process, as 
well as producing relevant numbers of CMs, without compromising their structural quality 
and functionality. To achieve this goal, different bioreactor systems and strategies were used, 
including single-use bioreactors with distinct agitation types, stirred tank bioreactors and 
automated continuous perfusion system. 
 The second objective was the development of cryopreservation and hypothermic 
storage strategies to ensure an efficient storage of CMs after mass production in 
environmentally controlled bioreactors. 2D and 3D approaches were evaluated using 
different cryopreservation and storage solution formulations. 
 Finally, bioprocess derived CMs were used to evaluate their potential as promising 
cell model systems in cardiotoxicity/cardioprotection assays. 2D and 3D approaches were 
tested during oxidative stress induction and cardioprotective pretreatments. Hydrogen 
peroxide and catechin were used as cardiotoxic and cardioprotective agent, respectively. 
 The thesis rational is schematically illustrated in Figure 2.1. 
 
 
Figure 2.1: Thesis rational. Aim of the thesis, strategies outlined and major readouts obtained. 
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3. Materials and Methods 
3.1 miPSC culture on feeder layers 
 In this study, a murine transgenic αPIG-iPSC line was used [134]. This cell line was 
genetically modified to integrate and stably express a transgene containing puromycin-N-
acetyl transferase and eGFP (enhanced green fluorescent protein) genes, both under control 
of the cardiac-restricted promoter α-MHC [134]. Murine iPSCs (miPSCs) were propagated as 
colonies in static conditions (6-well plates) on a monolayer of mitotically inactivated murine 
embryonic fibroblasts (MEFs, E14.5) in expansion culture medium (Dulbecco modified Eagle 
medium (DMEM) supplemented with 15% (v/v) Fetal Bovine Serum (FBS), 1% (v/v) 
Minimum Essential Medium – Non-Essential Amino Acids (MEM-NEAA), 2mM L-glutamine, 
50µM β-mercaptoethanol, 500μg/mL Geneticin (Neomycin sulfate/G418) (all from 
Invitrogen)) and 100 U/µL Leukemia inhibitory factor (LIF, Milipore). miPSC were cultured at 
37°C, in a humidified atmosphere of 5% CO2. Every 2-3 days, when miPSC colonies covered 
about 80% of the culture surface area, colonies were dissociated with 0.05% (w/v) 
Trypsin/EDTA (Invitrogen) for 5min at 37°C. After dissociation, miPSCs were plated onto 
MEFs feeders at a density of 0.125 - 0.25x106 cell/well.  
3.2 miPSC differentiation in fully controlled bioreactors 
3.2.1  miPSC differentiation in stirred tank bioreactor 
Aggregation Step: miPSC colonies were dissociated with 0.05% Trypsin/EDTA (as described 
above) and inoculated as single cells at a concentration of 0.7x105 cell/mL into an 
Erlenmeyer, in 100mL of differentiation medium (Iscove's Modified Dulbecco's Medium 
(IMDM) supplemented with 20% (v/v) FBS, 1% (v/v) MEM- NEAA, 1% (v/v) Penicillin-
Streptomycin (Pen/Strep), 50 µM β-mercaptoethanol (all from Invitrogen) and 100µM 
Ascorbic acid (Wako Chemicals GmBH)). miPSC cultures were placed on an orbital shaker, at 
80-90 rpm, and cultivated for 2 days at 37°C, in a humidified atmosphere of 5% CO2. 
Expansion and Differentiation Step: At day 2, cell aggregates were inoculated at a 
concentration of 150 aggregates/mL in computer-controlled stirred tank bioreactors 
(DASGIP Technology DS0200TBSC model, Eppendorf), equipped with a trapezoid impeller 
with arms, and with a working volume of 200mL. The headplate of the bioreactor has ports 
for pH and pO2 electrodes, allowing online measurement and control of parameters, ports for 
sampling tubes and for addition and/or removal of culture medium. The dissolved oxygen 
(DO) was controlled via surface aeration with Air and N2 - DO: 4% O2 (approximately 20% air 
saturation), surface aeration rate: 0.1vvm and CO2: 5%. Temperature was kept at 37°C using a 
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DASGIP TC4SC4 Control System via Bioblock by heating and cooling cycles. This control 
system was also used to promote intermittent agitation profiles (agitation rate: 90rpm) in 
these bioreactor cultures. Data acquisition and process control were performed using DASGIP 
Control Software 4.0. 
 At day 9, cell lineage selection of the cultures was induced by performing a partial 
medium exchange (50% v/v), replacing the culture medium for differentiation medium 
supplemented with 8µg/mL Puromycin (Invivogen). Two different process approaches for 
miPSCs-derived CM selection were evaluated and compared: A) semi-continuous (i.e. manual 
medium exchange) and B) continuous perfusion operation modes.  
A) Semi-Continuous system: Medium exchanges were performed, by partially replacing 
culture medium for fresh differentiation medium supplemented with Puromycin (8µg/mL), at 
days 12 (70% v/v) and 14 (50% v/v). In addition, at day 12, the bioreactor working volume 
was reduced to 100mL. Medium exchanges were performed by stopping agitation and 
allowing CM aggregates to settle (2-3min with no agitation). 
B) Continuous Perfusion system: A fully automated continuous perfusion system was 
incorporated using computer controlled peristaltic pumps. The perfusion apparatus (Figure 
3.1) included a DASGIP MP8 Multi Pump module, one port for the inlet and one port for the 
outlet, one computer, the bioreactor vessel, the inlet and outlet containers and their 
respective scales. The weight in each scale was continuously monitored to ensure a precise 
control of perfusion rates throughout the culture. Two perfusion rates were tested as 
summarized in table 3.1, represented as dilution rates (      , where F is the perfusion 
rate used and V is the working volume). 
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Figure 3.1: Perfusion apparatus used in continuous perfusion experiments. 
 
Table 3.1: Dilution rates tested in the continuous perfusion system approach. 
Strategy 
Dilution Rate (D; day-1) 
day 9 – 12 day 12 - 14 day 14 - 16 
I) Low Perfusion rate 0.14 0.36 0.24 
II) High Perfusion rate 0.70 1.80 1.20 
 In both strategies evaluated, CM aggregates were harvested from stirred tank 
bioreactors at day 16. These aggregates were dissociated into single cells by incubation with 
0.25% (w/v) Trypsin/EDTA and then transferred to 2D static culture systems (6-, 24- or 48-
well plates). CMs were cultured in differentiation medium on surfaces coated with CELLstart 
CTS (Invitrogen), according to manufacture instructions. Cells were cultivated in incubators 
at 37°C, in a humidified atmosphere of 5% CO2, until further analysis.  
3.2.2  Disposable single-use bioreactors 
 CM differentiation of miPSCs was also evaluated in two types of disposable single-use 
computer controlled bioreactors: 1) wave agitated bioreactor (WAVE BioreactorTM 20/50 and 
WAVEPODTM II; GE Healthcare) and 2) pneumatically mixed bioreactor (Pneumatic 
Bioreactor System, PBS 3 Air-Wheel Bioreactor System; PBS Biotech). 
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1) Wave Bioreactor: miPSCs were inoculated in the wave CellbagTM (GE Healthcare) as single 
cells, at a concentration of 0.7x105 cell/mL, under defined conditions (temperature: 37°C; DO: 
4% O2, approximately 20% air saturation; CO2: 5%; surface aeration rate: 0.1vvm; rocking 
angle: 4°; agitation rate: 10-26rpm). Cells were cultured in differentiation medium 
supplemented with 100µM Ascorbic acid and 0.025% (v/v) Antifoam C emulsion (Sigma-
Aldrich). Different starting volumes were evaluated, namely 300mL and 500mL. At day 2, 
aggregate concentration was adjusted to yield 150 aggregates/mL by increasing the working 
volume of the culture up to 500mL and 1000mL respectively. At day 9, cell lineage selection 
was induced by performing a partial medium exchange (50% v/v) by replacing culture 
medium for fresh differentiation medium supplemented with 8µg/mL Puromycin. At day 11, 
the produced miPSC-derived CMs were harvested, dissociated and transferred to 2D culture 
systems, as described above (Section 3.2.1), for cell characterization and functionality tests. 
Data acquisition and process control were performed using UNICORN DAQ 1.0 Control 
Software.  
2) Pneumatically mixed Bioreactor: The aggregation step was performed in Erlenmeyers 
(shake flasks) as described above (Section 3.2.1). At day 2, miPSC aggregates were inoculated 
at 150 aggregate/mL in the PBS bioreactor under defined conditions (temperature: 37°C; DO: 
4% O2, approximately 20% air saturation; CO2: 5%; surface aeration rate: 0.1vvm via micro 
and macrosparger). Cells were cultured in differentiation medium supplemented with 100µM 
Ascorbic Acid and 0.025% (v/v) Antifoam C emulsion. Stirring rate was kept between 15-32 
rpm. At day 9, cells were harvested from the bioreactor. Data acquisition and process control 
were performed using PBS Biotech Control Software (VxWorks OS). 
3.3 Cryopreservation and hypothermic storage of CMs derived from miPSC 
 CMs derived from miPSCs were cryopreserved using different freezing solutions: 
Cryopreservation medium (90% FBS and 10% (v/v) Dimethyl Sulfoxide (DMSO; Sigma-
Aldrich)), CryostorTMCS10 (Stem Cell Technologies) and PRIME-XV (Irvine Scientific). Before 
cryopreservation using the FBS+10% DMSO formulation, CMs were pretreated with 10μM of 
Rho-associated kinase inhibitor (ROCKi; Millipore), diluted in differentiation medium, for 1 
hour at 37°C. In addition, a low temperature storage solution (hypothermic storage: 2-8°C) 
was also tested, HypoThermosol®-FRS (BioLife Solutions Inc.). Cryopreservation and low 
temperature storage were tested in 2D cell monolayers and 3D aggregate systems. 
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3.3.1  Cryopreservation of 2D monolayers 
Freezing: Cells were plated at 1x106cell/well in 24-well plates, coated with CELLstart, and 
maintained for 7 days in culture. At day 7, cells were cryopreserved in 300µL of freezing 
solution (mentioned above) using a controlled rate freezer, Planer Kryo 560-16 (Cryo), using 
the following program: 1) Hold temperature at 4°C for 20min; 2) Initiate temperature 
decrease at a freezing rate of -1°/min until -80°C. 
Thawing: Cryopreserved cells were thawed in a 37°C water bath and a three-step dilution 
(1:1, 1:2 and 1:4) in differentiation medium was performed in order to dilute the DMSO while 
reducing the osmotic shock. Post-thaw studies were performed directly in the cell plates.  
3.3.2  Cryopreservation of 3D aggregates 
Freezing: CM aggregates were transferred to cryovials at 300 aggregate/vial and 700µL of 
freezing solution (mentioned above) was added to each vial. Aggregates were allowed to 
equilibrate in the freezing solution for 20min at 4°C. Samples were frozen to -80°C in an 
isopropanol-based freezing system (“Mr. Frosty”, Nalgene), at a cooling rate very close to 1°C 
per minute, and stored in the gas phase of liquid nitrogen (LN2) reservoir until their thawing. 
Thawing: Following cryopreservation, cells were quickly thawed placing cryovials in a 37°C 
water bath. A three-step dilution (1:1, 1:2 and 1:6) in differentiation medium was performed 
immediately after thawing. Aggregates were then transferred to 12-well plates for post-thaw 
studies.  
3.3.3  Hypothermic storage of CMs derived from miPSC 
 miPSC-derived CMs were stored in HypoThermosol®-FRS as 2D cell monolayers and 
3D aggregates. CMs were plated at 1x106cell/well, in coated 24-well plates, and aggregates 
were transferred to cryovials at 300 aggregate/vial. For these approaches, 300µL and 700µL 
of storage solution was added, respectively. CMs were stored at 4°C during 7 days. After this 
period, storage solution was removed, CMs were washed once with warm medium and 
differentiation medium was added. Stored aggregates were transferred to 12-well plates and 
post-thaw studies were carried out in 2D and 3D stored cells. 
3.3.4  Assessment of cell recovery of CMs  
Cell recovery was assessed with PrestoBlueTM assay (thoroughly explained in Section 3.5) 
before freezing, after thawing and during days 1, 3 and 7 of the post-thawing process. Results 
were expressed in terms of percentage of cell recovery in relation to the control (cells before 
freezing). Medium exchanges were performed at days 1, 3 and 7. 
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3.4 Cardiotoxicity and cardioprotective assays 
 miPSC-derived CMs were inoculated at 105cell/well in 48-well plates coated with 
CELLstart, for 2D cell monolayers, and approximately 5 Agg/well, for 3D experiments. In both 
approaches cells were cultured in differentiation medium. 
Cardiotoxicity assay: To induce oxidative stress, CMs were incubated with hydrogen peroxide 
(H2O2; Sigma-Aldrich) diluted in differentiation medium for 20 hours, using concentrations 
ranging from 50-900µM. After incubation, cells were washed 3 times with warm Phosphate-
buffered saline (PBS; Invitrogen) and cell viability was assessed before and after stress 
induction with PrestoBlueTM assay (Section 3.5). Results were expressed in terms of 
percentage of cellular viability in relation to the control (cells incubated with differentiation 
medium only).  
Cardioprotective assay: Cardioprotective evaluation assay was performed using an 
antioxidant compound, catechin. CMs were pretreated with catechin diluted in differentiation 
medium for 24 hours, using different concentrations: 150mg/L and 300mg/L. After 
pretreatment, cells were washed 3 times with warm PBS and oxidative stress was induced 
with H2O2 (400 and 500μM) for 20 hours. Control wells were performed with differentiation 
medium only and with differentiation medium supplemented with H2O2. Cell viability was 
assessed three times: i) before catechin pretreatment; ii) after catechin pretreatment and iii) 
after oxidative stress incubation. Results were expressed in terms of percentage of cellular 
viability in relation to the control (cells incubated with differentiation medium only). 
3.5 Cell viability evaluation 
Cell Membrane Integrity assay: Culture viability was assessed using 2 enzyme substrates: 
fluorescein diacetate (FDA; Sigma-Aldrich) and propidium iodide (PI; Sigma-Aldrich). Cells 
were incubated with 20µg/mL FDA and 10µg/mL PI in PBS for 2-3min and then visualized 
using fluorescence microscopy (DMI6000, Leica). FDA is a non-polar, non-fluorescent 
fluorescein analogue which enters all cells freely. In viable cells, FDA is converted by 
intracellular esterases to highly fluorescent fluorescein and confers cells green fluorescence. 
PI is a polar, red colored fluorescent compound that only enters cells with lack of membrane 
integrity, intercalating with DNA and therefore nucleus dying/dead cells stain red [135]. 
Trypan Blue exclusion method: Total number of viable cells was determined after incubation 
with 0.1% (v/v) Trypan Blue dye (Invitrogen) in PBS. Using a Fuchs-Rosenthal 
haemocytometer chamber, cells with damaged membranes (non-viable) stain blue in 
presence of this compound. 
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Lactate Dehydrogenase (LDH) activity: LDH activity, from the culture supernatant, was 
determined following spectrophotometrically (at 340 nm) the rate of oxidation of NADH to 
NAD+ coupled with the reduction of pyruvate to lactate. The specific rate of LDH release 
(qLDH) was calculated for each time interval using the following equation:      
             , where      is the change in LDH activity over the time period   , and 
    is the average of the total cell number during the same period. The cumulative value 
qLDHcum was estimated by qLDHcum i+1 = qLDH i + qLDH i+1. This assay is a useful tool to 
monitor cell lysis since LDH is an intracellular enzyme that is only presented in culture 
supernatant when the cell membrane is damaged.   
PrestoBlueTM assay: Metabolic activity was determined using the metabolic indicator 
PrestoBlue reagent following the manufacture’s recommendation (Invitrogen). Briefly, cells 
were incubated for 1-2 hours with fresh culture medium containing 10% (v/v) PrestoBlue 
reagent. Fluorescence was measured (excitation wavelength: 570 nm, emission wavelength: 
585 nm) using a microwell plate fluorescence reader FLx800 (Biotek). The active ingredient 
of prestoBlue (resazurin) is a nontoxic non-fluorescence indicator dye that is converted to 
red-fluorescent resorufin via the reduction reaction of metabolically active cells. Produced 
fluorescence is proportional to the number of live and metabolic active cells. Thus, PrestoBlue 
assay provides a quantitative measure of cell viability and metabolic activity. 
3.6 Evaluation of aggregate concentration and size 
 The number of total aggregates and eGFP positive aggregates were counted in 4-6 
wells of a 24-well plate, containing 250-400μL of culture samples, using a phase contrast and 
fluorescence inverted-microscope (Leica Microsystems GmbH). Using this microscope and 
ImageJ software, aggregate size was determined by measuring two perpendicular diameters 
of each aggregate, from a minimum of 30 aggregates. These measures were used to calculate 
the average diameter of each aggregate. Aggregates with less than 20μm diameter, generally 
duplets or triplets, were not considered. 
3.7 Culture yields determination 
Expansion Fold (Cells/miPSCs): Fold increase (FI) in cell concentration was determined 
based on the ratio Cellsday9/input miPSCs, where Cellsd9 is the total cell number at day 9 and 
input miPSCs is total cell number at day 0 (i.e. cell inoculum).  
Differentiation Yield (CMs/miPSCs): Differentiation yield was determined based on the ratio 
CMsd16/input miPSCs, where CMsday16 is the total number of GFP positive cells on day 16 and 
input miPSCs is total cell number at day 0 (i.e. cell inoculum).  
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CMs generated per liter of culture medium throughput (CMs/L): CMs generated per liter of 
culture medium throughput was determined based on the ratio CMsday16/Vtotal, where CMsday16 
is the total number of GFP positive cells on day 16 and Vtotal is the total volume of 
differentiation medium used in the bioprocess. 
Cell recovery (%): Cell recovery was determined based on the ratio CMsd16/Cellsd9 (in terms 
of percentage), where CMsday16 is the total number of GFP positive cells on day 16 and Cellsd9 
is the total cell number at day 9 (before CM selection) 
3.8 Characterization of miPSCs and miPSC-derived CMs 
Alkaline Phosphatase (AP) Staining: Undifferentiated PSCs are characterized by high 
expression levels of alkaline phosphatase (AP). Cultures were stained using an AP activity 
detection kit (Millipore) according to the manufacturer’s instructions and observed under 
phase contrast microscopy. Positively stained miPSCs (purple) were considered 
undifferentiated cells. 
3.8.1  Structural characterization 
Immunocytochemistry: miPSCs cultures were fixed in 4% (w/v) paraformaldehyde (PFA, 
Sigma‐Aldrich) in PBS for 20min, permeabilized for 15min with 0.1% (w/v) Triton X‐100 
solution (Sigma‐Aldrich), for Oct-4, and incubated with primary antibody overnight at 4°C in 
0.125% (w/v) fish skin gelatin (FSG, Sigma-Aldrich) in PBS. Primary antibodies used were: 
Oct-4, SSEA-1 (1:200, all Santa Cruz Biotechnology) and SOX2 (1:500, Millipore). Cells were 
washed three times in PBS and the secondary antibodies were applied to the cells for 60min 
at room temperature in the dark. After three washes with PBS, cell nuclei were 
counterstained with Hoechst 33432 (Sigma-Aldrich). Secondary antibodies used were: 
AlexaFluor 488 goat anti-mouse IgG and AlexaFluor 488 goat anti-mouse IgM (1:200 dilution 
in 0.125% (w/v) FSG in PBS; both antibodies from Invitrogen). 
  CM cultures were fixed in 4% (w/v) PFA in PBS for 20min, permeabilized for 10min 
with 0.5M Ammonium chloride (Sigma-Aldrich), 0.25% Triton X-100 in PBS at room 
temperature and blocked with 5% FBS in PBS for 60min at room temperature. Cells were 
incubated with primary antibody overnight at 4°C in 0.8% (w/v) bovine serum albumin (BSA, 
Sigma-Aldrich) in PBS. Primary antibodies used were: α-sarcomeric actinin (1:200, Sigma-
Aldrich), titin (1:100, Santa Cruz Biotechnology), troponin I (TnI, 1:100, Millipore) and anti-
atrial natriuretic peptide (ANP, 1:200, Millipore). Cells were washed in PBS and secondary 
antibodies were applied for 60min at room temperature in the dark. Secondary antibodies 
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used were: AlexaFluor 594 goat anti-mouse IgG (1:200 dilution in 0.8% (w/v) BSA (Sigma-
Aldrich) in PBS, from Invitrogen). Nuclei staining was assessed using Hoechst. 
Flow Cytometry analysis: For SSEA-1 (stage-specific embryonic antigen-1) positive cell 
analysis, miPSC colonies were dissociated into single cells with 0.05% (w/v) EDTA/Trypsin 
and afterwards resuspended in washing buffer (WB) solution (5% (v/v) FBS in PBS). After 
two washing steps, cells were incubated with the primary antibody, SSEA-1 (1:10 in PBS), for 
1 hour at 4°C, washed three times in WB and then incubated with the secondary antibody, 
AlexaFluor 488 goat anti-mouse IgM (1:200), for additional 30min at 4°C, After two washing 
steps with WB, cells were resuspended in WB and analyzed in a flow cytometry instrument 
(CyFlow space, Partec). Ten thousand events were registered per sample.  
 For eGFP positive cell analysis, cell aggregates were dissociated into single cells with 
0.25% (w/v) Trypsin/EDTA and afterwards resuspended in WB solution. Cells were 
incubated for 2min with PI (1:1000) and analyzed in the flow cytometry instrument. The 
percentage of eGFP positive cells reflects culture purity throughout the differentiation 
process. Ten thousand events were registered per sample.  
Semiquantitative and quantitative RT-PCR: Aggregates were sedimented, washed with PBS 
and centrifuge at 300 x g for 5min. The pellet was snap-frozen by immersion in liquid 
nitrogen. Total RNA was extracted using the High Pure RNA Isolation Kit (Roche), and reverse 
transcription was performed with High Fidelity cDNA Synthesis Kit (Roche), following 
manufacturer’s instructions. Gene expression profiles of various markers during cardiac 
differentiation were analyzed by RT-PCR using the DreamTaq Green PCR Master Mix 
(Thermo Scientific). In 20µL reactions with final primer (Table 7.1 – Section 7, Page 77) 
concentrations of 0.5µM, 1µL of cDNA template was used. After RT-PCR, 10µL of the reaction 
were loaded on a 1.5% agarose (Invitrogen) gel. Bands were detected with a CCD camera 
using Intas UV-System and Intas GDS application (Intas). Relative quantification of gene 
expression was performed using SYBR Advantage qPCR Premix (Clontech) in 10μL reactions 
with a 1:25 diluted cDNA template and 0.2μM final primer concentrations. The reactions 
were performed in 384-well plates using AB 7900HT Fast Real Time PCR System (Applied 
Biosystems). Cycle threshold (Ct’s) and melting curves were determined by SDS 2.1 Software. 
All data was analyzed using the comparative CT method (2-ΔΔCt method) for relative gene 
expression analysis. Changes in gene expression were normalized to GAPDH gene expression 
as internal control. 
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3.8.2  Functional characterization 
Electrophysiological Characterization: Purified CMs were washed twice with PBS (Invitrogen) 
and dissociated using 0.05% Trypsin/EDTA (Invitrogen) 2 days before measurement. Single 
CMs were plated on glass cover slips coated with 0.1 % gelatin. Patch clamp-experiments 
were performed as described previously [136]. Briefly, the cover slips were placed into a 
recording chamber (37°C) and cells were continuously perfused with extracellular solution 
(as described in [136]). Cell membrane capacitance was determined online using Pulse 
software (Heka Elektronik). Action potential (AP) recordings of spontaneously beating CMs 
were performed utilizing the whole-cell current-clamp technique with an EPC-9 amplifier 
(HEKA Elektronik) and operated through the Pulse acquisition software. Response to 
hormonal regulation was analyzed by administering 1 µM isoproterenol and 1 µM carbachol 
(both from Sigma-Aldrich). 
Detection of Ca2+ Transients: Ca2+ imaging was performed according to the standard protocol 
provided in Rhod-3- Calcium Imaging kit (Invitrogen). Briefly, cells were labeled with Rhod-3 
for 1h at 37°C, washed twice in PBS, incubated for 1h with a water-soluble reagent to reduce 
baseline signal and washed again in PBS. Cells were imaged live using a spinning disk 
confocal microscope (Nikon Eclipse Ti-E; System: Andor Revolution XD; Confocal Scanner: 
Yokogawa CSU-x1) and Calcium transients were determined using Micro-Manager 1.4 and 
ImageJ softwares. 
3.9 Statistical analysis 
 Statistical analysis was determined with a single-factor analysis of variance (ANOVA), 
using Microsoft Excel’s data-analysis toolpack (Microsoft Corporation). Three independent 
experiments were performed. A 95% confidence level was considered to be statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Results and Discussion 
 
 37 
 
4. Results and Discussion 
4.1 Bioprocess engineering of miPSCs 
4.1.1  Production of miPSC-derived CMs in fully controlled bioreactors 
 The first task of this thesis was the development of a robust, scalable and integrated 
strategy for the production and selection of CMs derived from miPS cells. For this purpose, a 
murine transgenic αPIG-iPS cell line was used. This cell line was genetically modified to 
integrate and stably express a transgene containing puromycin-N-acetyl transferase and 
eGFP genes, both under control of the cardiac-restricted promoter alpha myosin heavy chain 
(α-MHC). This characteristic enables an easy monitoring of the cardiac differentiation 
process, by assessing GFP expression over time (by fluorescence microscopy and/or flow 
cytometer analyses), and CM selection upon addition of puromycin in the culture media. 
Some studies have shown that this cell enrichment approach is highly efficient, capable of 
obtaining pure populations of PSC-derived CMs [102, 103].   
 miPSCs were propagated as colonies on monolayers of inactivated feeder cells (mouse 
embryonic fibroblast; MEFs). These feeder cells support the growth of pluripotent stem cells 
by producing growth factors and providing adhesion molecules and ECM components for cell 
attachment [46]. Medium is supplemented with LIF to further maintain the cells pluripotent 
state throughout propagation [137]. Before initiating the differentiation and CM production 
procedure, the undifferentiated state and pluripotency of miPSCs was evaluated by 
immunofluorescence microscopy, flow cytometry analysis and by alkaline phosphatase 
activity test (Figure 4.1).  
 
Figure 4.1: Characterization of miPSCs. A) Immunofluorescence images of Oct-4, SSEA-1 and SOX2 
labeling, and phase contrast picture of alkaline phosphatase activity. Nuclei were labeled with Hoechst 
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33432 (blue). Scale bars: 100 µm. B) Histogram obtained in flow cytometry analysis of SSEA-1 positive 
cells before bioprocess initiation. 
 Figure 4.1A shows that miPSCs stained positive for specific stem cell markers (OCT-4, 
SSEA-1 and SOX2) and presented alkaline phosphatase activity. The percentage of SSEA-1 
positive cells was high (98%, Figure 4.1B), indicating that almost the entire population had an 
undifferentiated and pluripotent phenotype. 
 Different bioreactor designs were evaluated and compared in terms of their ability to 
support miPSC growth and CM differentiation namely, stirred tank bioreactor (Stirred Tank 
BR), Wave bioreactor (Wave BR) and a pneumatically mixed bioreactor (PBS BR). All these 
bioreactor systems are capable of an automated process control, online measurement and 
adjustment of the culture parameters. Stirred tank BRs have been widely used in the 
pharmaceutical industry and more recently in  stem cell biomanufacturing  [15]. Wave and 
PBS BR are single-use technologies that offer unique advantages for the bioprocessing of 
stem cells, such as a low shear stress environment, improved mass and oxygen transfer, rapid 
medium homogeneity and unique agitation types (as previously mentioned in Section 1.2.6). 
 In these experiments, miPSCs were cultivated in 4% dissolved oxygen (hypoxia 
conditions). Our group and others have shown that low oxygen tensions/concentrations (2-
5%) enhance PSC proliferation [67, 68] and CM differentiation [69, 70]. In fact, during 
cardiomyogenesis, many cues and processes are influenced by hypoxia conditions (reviewed 
in [138]). Therefore, hypoxia conditions were used in all tested bioreactors aiming to favor 
cell expansion and CM-lineage differentiation.  
 Recent evidences suggest that mechanical stimulation enhances CM differentiation of 
PSCs, contractile function and up-regulates cardiac gene expression [139, 140]. Thus our 
strategy consisted in varying the agitation type and profile on each bioreactor system to 
promote cyclic mechanical stimuli to the cells and ultimately potentiate their differentiation 
towards CMs.  
 miPSCs were cultured in bioreactors as 3D aggregates, as this approach has been 
shown to enhance cell differentiation and functionality [79]. Cell aggregation step was 
performed in Erlenmeyer flasks for 2 days. At day 2, miPSC aggregates presented high 
viability and an average size of 155μm, ranging from 70 to 270μm (Figure 4.2); these 
aggregates were transferred to Stirred Tank and PBS BR at a final concentration of 150 
aggregates/mL in a working volume of 200mL and 2L, respectively. The Wave BRs were 
inoculated with single cells and cell aggregation step was promoted inside the CellbagTM. By 
day 2, cell aggregates presented high cell viability and similar size distribution as the ones 
produced in Erlenmeyer flasks (Figure 4.2).  Aggregate concentration was adjusted in the 
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Wave BR to yield 150 aggregates/mL, by addition of differentiation medium (Materials and 
Methods, section 3.2.2).  
 
Figure 4.2: miPSCs aggregation step. Cell aggregation was evaluated in Erlenmeyer flasks and in the 
Wave BR. A) Viability analysis of miPSCs aggregates at day 2 using FDA (live cells, green) and PI (dead 
cells, red). Scale bars: 200 μm. B) Comparison of aggregate size at day 2.  
 Two working volumes were tested in Wave BRs: 0.5L and 1L. In all culture systems, 
cell aggregates were cultured in the presence of ascorbic acid for additional 7 days. At day 9, 
CM lineage selection was promoted by addition of puromycin to the culture medium. 
Cardiospheres (pure CM aggregates) were harvested at day 11, in Wave BRs, and at day 16, in 
Stirred Tank BRs. Figure 4.3 presents an overview of the differentiation process. 
 
Figure 4.3: miPSC differentiation into CMs using different bioreactor systems. Different 
bioreactor systems were tested for their capacity to support expansion and cardiomyocyte 
differentiation of miPSC: stirred tank bioreactor (Stirred Tank BR); wave-induced bioreactor (Wave 
BR); pneumatically mixed bioreactor (PBS BR). Phase contrast and fluorescence images showing cell 
aggregates with eGFP+ cells (green) at days 7, 9, 11 and 16 of the cultures. Scale bars: 200 μm.  
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 The results show that Stirred Tank and Wave BRs were the most suitable culture 
systems for miPSC-derived CM production. miPSCs cultivated in both bioreactors were able 
to proliferate and differentiate into CMs (Figure 4.3 and 4.4A). By the end of both processes 
pure populations of eGFP positive and beating aggregates were achieved (>96% eGFP 
positive cells, Table 4.1).  
 On the other hand, the PBS BR revealed to be an unsuitable culture system for miPSC 
differentiation. Aggregate concentration in PBS BR decreased rapidly until day 9 (Figure 
4.4B) and the presence of eGFP positive cells was rarely observed until day 9 of culture 
(Figure 4.3). In addition, during culture time cell deposition on the bioreactor vessel was 
observed (Annex 2; Section 7 Figure 7.1). According to the manufacturer’s instructions, the 
used PBS BR model (PBS3) is appropriate for cultivating cells in working volumes from 1.5 to 
3L. In our experiments, PBS BR started with a 2L working volume. However, to monitor the 
culture, extensive sampling was collected throughout culture time, leading to a reduction in 
the working volume (below 1.8L). This resulted in unexpected foam formation due to the air-
wheel mixing above the gas-liquid interface (Annex 2; Section 7 Figure 7.1). In addition, the 
air-wheel mixing mechanism captures rising bubbles, from macro sparging, and converts 
them into rotational mixing power. Bioreactor sparging is used as a method to efficiently 
supply oxygen to cells [141]. However, bioreactor sparging and foam formation are 
responsible for bubble-associated damage [141] (e.g. bubble formation at sparger, bubble 
burst at fluid surface) which presents major damage to animal cells that lack a protective cell 
wall [142]. Although an antifoam emulsion was added, adverse effects from foam formation 
occurred. These results suggest that higher concentrations of this antifoam agent should be 
tested, as antifoam must be supplied in sufficient quantity to prevent foam formation during 
air-wheel mixing of the bioreactor. 
 Figure 4.4 presents the main results obtain from the previous BR processes. 
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Figure 4.4: Production of miPSC-derived CMs using fully controlled bioreactors. Main results 
obtained from miPSC bioprocessing using different environmentally controlled bioreactor systems. 
Profiles of cell concentration (A), aggregate concentration (B) and aggregate size (C) during culture 
time. D) Fold increase in LDH release cumulative values until culture day 9.  
As mentioned before, two different working volumes were tested in Wave BR, namely 
0.5 and 1L. Figure 4.4A shows that 1L is the most suitable working volume for expansion and 
differentiation of miPSCs into CMs, since higher cell numbers were achieved throughout the 
culture. In addition, Wave BR 1L resulted in an overall bioprocess improvement, achieving a 
3.8-fold increase in mIPSC expansion (72.9 Cellsday9/input miPSCs) and a 5.3-fold higher 
differentiation yield (60.1 CMs/input miPSCs) over the Wave BR 0.5L. Nonetheless, the Wave 
BR 0.5L was also able to produce highly pure CMs (97%; Table 4.1). On the other hand, when 
a working volume of 0.5L was used with the Wave BR, cell/aggregate deposition on the sides 
of the CellbagTM was observed (Annexes 2; Section 7 Figure 7.1), resulting in a 2-fold higher 
cell lysis until day 9 (Figure 4.4D). Fold increase in LDH release was calculated until day 9, 
since from this timepoint onwards antibiotic selection was induced, and cell death also 
resulted from antibiotic-based selection. According to the manufacturer’s instructions, the 
used CellbagTM is appropriate for cultivating cells with working volumes between 0.1 and 1L. 
However, our results showed that for the cultivation of miPSCs as cell aggregates, 0.5L is not 
appropriate and higher working volumes should be used.  
 The results show that both, Stirred Tank and Wave BRs, enhanced cell proliferation. 
Although higher cell concentrations were observed in the Wave BR 1L (Figure 4.4A), similar 
expansion folds were obtained on both bioreactors (Table 4.1 - Stirred Tank BR: 72.4 
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Cellsday9/input miPSCs; Wave BR 1L: 72.9 Cellsday9/input miPSCs). However, the Stirred Tank 
BR presented a higher fold increase in LDH accumulation, achieving a 5.8-fold increase when 
compared to the Wave BR 1L, which is in fact the highest LDH release obtained from the 
compared bioprocesses (Figure 4.4D). This difference in LDH release may be related to shear 
stress issues. Wave BRs have been shown to promote a lower shear stress environment when 
compared to standard Stirred Tank BRs, due to its gentle rocking motion [94]. Since a wave-
induced agitation presents less shear damage to cells/aggregates, higher cell viabilities may 
be obtained in Wave BR than in Stirred Tank BR cultures. In contrast to the Stirred Tank BR, 
higher cell concentration and lower aggregate concentration was observed in Wave BR 1L 
during differentiation time (Figure 4.4A-B). The Wave BR 1L presented higher aggregate 
sizes (around 450μm on days 9 and 11, Figure 4.4C), and consequently higher number of cells 
per aggregate. For example, by day 9, aggregates from Wave BR 1L were composed by 
3x104cell/agg, as for aggregates from Stirred Tank BR were only composed by 8x103cell/agg. 
The higher aggregate sizes (600/800μm) observed in Wave BR, may be due to some 
aggregate fusion promoted by the gentle wave-induced agitation characteristic of these 
bioreactors. Nevertheless, no harmful cell clumping or necrotic centers were observed in 
Wave BR 1L culture (Figure 4.4A). 
 To analyze the effect of different agitation types on miPSCs differentiation towards 
CM lineage, differentiating cells were characterized based on their gene expression and levels 
of eGFP positive cells, throughout the process. RT-PCR and flow cytometry analyses were 
performed to compare/evaluate cardiomyocyte differentiation throughout culture time in 
both Stirred Tank and Wave BRs. RT-PCR analysis confirmed that miPSCs differentiated 
earlier into CMs in the Wave BR, as an earlier and enhanced expression of mesoderm and 
cardiac specific genes was observed, when compared to the Stirred Tank BR (Figure 4.5A). 
The expression of the pluripotent gene Oct-4 decreased more rapidly, reaching very low 
levels on day 6 of differentiation and undetectable levels from day 8-9 onwards (Figure 4.5A). 
In contrast, Oct-4 is still highly expressed at this stage of differentiation in the Stirred Tank 
BR and was only undetectable in the purified CMs. T-Brachyury, a mesodermal marker, 
reached a peak of expression earlier in the Wave BR (day 4). Also, the expression of the 
cardiac specific markers (cTnT, Nkx2.5, HCN4, Myl2 and Myl7) was detected earlier in Wave 
cultures. These findings are in agreement with the results obtained in flow cytometry 
analysis. In Wave bioreactor cultures, eGFP positive cells were detected from day 5 onwards. 
For example, by day 7, 46% of the cells were eGFP positive whereas in Stirred Tank BR, at the 
same timepoint, only few cells were eGFP positive (Figure 4.5B). In addition to earlier 
expression of cardiac specific markers in Wave cultures, greater band intensities were also 
observed before CM selection (day 9), indicating a substantial enhancement in the expression 
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of the cardiac specific markers in Wave cultures when compared to Stirred Tank cultures. At 
this timepoint, RT-qPCR also confirmed that cTnT and Myl7 were highly expressed in Wave 
BRs than in Stirred Tank BR (Figure 4.5C). These results corroborate with the percentage of 
eGFP positive cells determined at day 9. Before CM selection, the percentage of eGFP positive 
cells in the Wave BR (82%) was 2.5-fold higher when compared to the Stirred Tank BR (32%; 
Figure 4.5B). Consequently, only 2 days of antibiotic treatment were sufficient to obtain a 
pure CM population (>97% eGFP positive cells) in Wave bioreactors whereas 7 days were 
required to reach the same purity in the Stirred Tank BR (Figure 4.5B). At the end of both 
bioprocesses, expression of cTnT reached similar levels, whereas Myl7, a marker of atrial-like 
CMs, presented higher expression in Wave cultures (Figure 4.5C).  
 
Figure 4.5: Evaluation of gene expression and levels of eGFP positive cells during CM production 
in Stirred Tank and Wave BRs. RT-PCR was used to assess changes in gene expression during miPSC 
expansion and differentiation into CMs. Flow cytometry was assessed to quantify the levels of eGFP 
positive cells during culture time. A) Semiquantitative RT-PCR analyses demonstrating the expression 
of pluripotency (Oct-4), endoderm (AFP), mesoderm (T-Bra) and CM-specific (Nkx2.5, cTnT, HCN4, 
Myl2, Myl7) genes during the time course of differentiation process in Stirred Tank and Wave BRs. B) 
Percentage of eGFP+ cells during culture time, determined by flow cytometry analysis. C) Quantitative 
RT-PCR analysis of cells cultured in both Stirred Tank and Wave BRs, before CM selection (day 9) and 
at the end of the process (day 16 and 11 for Stirred Tank and Wave bioreactor cultures, respectively). 
Data was analyzed using the comparitive CT method (Stirred Tank, operating under continuous 
stirring, was used as a control). Significantly different results: P<0.05 (*) and P<0.01 (**). 
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The differences observed in Stirred Tank and Wave culture outcomes, including 
temporal gene expression patterns and eGFP positive cell levels, may be related with the 
specific agitation type of both BRs, and consequently with the frequency of stretch applied in 
both systems. In these experiments, miPSCs were subjected to distinct cyclic strains by 
varying the agitation type and profile used in BRs. In the Stirred Tank BR, using an 
intermittent stirring, cyclic tensions at frequencies close to 0.033Hz were promoted, whereas 
with a Wave-induced agitation higher frequencies were reached (0.43-0.45Hz). Cardiac cells 
experience mechanical strains with every heartbeat, i.e., at a pulsatile frequency close to 1Hz 
[143]. Therefore, inducing cyclic tensions at higher frequencies (closer to 1Hz) may favor 
cardiomyogenesis by better mimicking the physiological environment.  
 miPSCs were successfully differentiated into CMs using environmentally controlled 
bioreactors. The Stirred Tank and Wave BR processes developed herein showed promising 
results in the development of robust and scalable strategies for the production and 
purification/selection of CMs. Table 4.1 presents a quantitative characterization of the Stirred 
Tank and Wave BR processes. 
Table 4.1: Quantitative characterization of CM production derived from miPSCs using 
environmentally controlled bioreactors.  
Strategy Stirred Tank BR Wave BR 0.5L Wave BR 1L 
Cell inoculum (x106 cell) 4.3 20.9 38.9 
Expansion Fold (Cellsday9/input miPSCs) 72.4 19.2 72.9 
Differentiation Yield (CMsd16/input miPSCs) 29.7 11.5 60.2 
Total Cell Number (x106 cell) 133.2 248.0 2420.0 
Final CM Purity (%) 96.0 97.0 97.0 
Total CM Number (x106 cell) 127.9 240.6 2347.4 
Final CM number per Liter (x108 CMs/L) 3.0 3.2 16.5 
 
The high degree of heterogeneity observed in the differentiated population derived 
from PSCs represents a considerable hurdle towards the application of these cells in clinical 
applications. The transgenic enrichment strategy used in this thesis presents a possible 
solution for this issue, capable of producing highly pure CMs (96-97%). Genetic-based 
selection strategies have been shown to enrich stem cell derived populations (reviewed in 
[54]). However, these methods are not ideal for clinical applications, requiring genetic 
manipulations and the use of costly and time consuming processes (previously stated in the 
Introduction, Section 1.3.1). Non-genetic purification of CMs should be tested over the use of 
a transgenic enrichment strategy. For instance, an interesting approach could be to exploit 
the distinct metabolic requirements of CMs and non-CM cell types. Previous studies have 
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stated that it is possible to achieve a CM purity of 99% when using a glucose depleted culture 
medium containing abundant lactate [110]. As the Wave BR strategy achieves purity levels of 
81% before CM enrichment, this strategy could prove promising in the development of a non-
genetic purification step in the bioprocess developed herein.  
As previously discussed, in the Stirred Tank BR lower differentiation yields were 
obtained when compared to the Wave BR, possibly due to the lower cyclic strain frequencies 
(0.033Hz) applied in this BR. Nonetheless, it should be noted that Stirred Tank and Wave BR 
strategies developed herein presented higher differentiation yields when compared to the 
ones reported in literature: 3.77 CM/PSC [70], using a 0.25L DASGIP model; 6.4 [98] and 23 
CM/PSC [99], using a 2L Biostat Sartorius BR (see Table 1.2, Section 1.2.6). 
 The number of CMs generated per liter of culture medium throughput (CMs/L) is a 
common parameter used to measure the cost-effectiveness and scale-up potential of a stem 
cell bioprocess [99], in which expensive medium and growth factors are used. Thus, this 
value can be used to compare CM productivity of different stem cell bioprocesses. The Stirred 
Tank BR system showed the lowest CM productivity, 3.0x108 CMs/L. On the other hand, the 
Wave BR 1L, resulted in a 5.4-fold increase in CM productivity (16.5x108 CMs/L) over the 
Stirred Tank and in a 3.2-fold improvement over the highest productivity stated in the 
literature for mPSC-derived CMs production (5.1x108 CMs/L [99]).  
 All together, these results suggest that Wave BRs are preferable platforms for mass 
production of CMs since they allow to reach clinically relevant CM productivities in just one 
liter bioreactor run, present promising capacity to boost CM differentiation and  importantly 
result in a 5 days shorter differentiation protocol . 
4.1.2  Development of a perfusion strategy in a stirred tank bioreactor 
 The Stirred Tank BR was able to successfully produce pure CMs from miPSCs, 
nonetheless this BR strategy showed potential to be improved. Perfusion strategies have 
been developed and integrated in Stirred Tank BRs, ensuring constant media renewal of 
culture medium and removal of metabolic byproducts [70, 96]. In addition, continuous 
perfusion-feeding ensures optimal process uniformity with respect to temperature, pH and 
dissolved oxygen, avoiding the fluctuation in pH and gas composition that normally occurs 
upon manual medium exchanges [99]. This approach also presents potential for the 
development of more robust purification/selection protocols, ensuring a culture free of cell 
debris at the end of the bioprocess. Perfusion strategies have also been developed for single-
use disposable bioreactors. However these technologies are still emerging and therefore 
present high costs and complex devices [144, 145]. 
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 With the objective of developing an integrated stirred tank bioreactor approach, with 
a continuous and automated perfusion system, computer controlled peristaltic pumps with 
gravimetric control were used. This strategy was integrated during the selection step of the 
process (i.e. from day 9 onwards). Perfusion rates are an important factor when developing 
perfusion strategies. Two different perfusion rates were tested: 1) Perfusion rates 
reproducing the medium exchanges of the semi-continuous Stirred Tank BR process (D= 
0.14-0.36day-1); 2) Perfusion rates 5 times higher (D= 0.7-1.8day-1). Figure 4.6 presents the 
main results obtained from these experiments.  
 
Figure 4.6: Production of miPSC-derived CMs using a continuous perfusion strategy. Different 
perfusion rates were tested: Low perfusion rate (mimics Stirred Tank BR medium exchanges) and high 
perfusion rate (5 times the rates used for the low perfusion rate). Continuous perfusion and the 
previous Stirred Tank strategy were compared from day 9 until the end of the process. A) Cell recovery 
at day 16. B) Fold increase in LDH release cumulative values during CM selection. C) Percentage of 
eGFP+ aggregates during selection. D) Phase contrast and fluorescence images showing eGFP+ cells 
(green) and single cells/cell debris present in the culture supernatant at different time points of the 
selection process. Scale bar: 200 μm.  
 The results show that using a continuous perfusion strategy during the selection step 
presents no adverse effects on culture outcome. Cell recovery during selection was similar 
using both perfused and manual medium exchange approaches, reflecting no meaningful cell 
loss due to the perfusion strategy (Figure 4.6A). Also, the continuous addition of fresh 
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medium with puromycin did not compromise cell viability during antibiotic selection, as no 
relevant differences were observed in LDH release in perfused and non-perfused bioreactors 
(Figure 4.6B). Similar profiles of eGFP positive aggregates were achieved in all the tested 
strategies (Figure 4.6C), showing that the developed perfusion approaches did not 
compromise cardiac differentiation potential in relation to the previous developed semi-
continuous process. In addition, the perfusion rates used in this work did not affect culture 
purity and CM differentiation yields. 
 Despite similar culture outcomes, using a higher perfusion rate strategy, a clean 
culture with no cell debris was obtained at day 16 (Figure 4.6D). In contrary, the lower 
perfusion strategy was not able to effectively remove cell debris during the selection step. By 
day 16 single cells and cell debris were observed in higher extend in culture supernatant. 
This is a major drawback in continuous integrated industrial processes, as this bioprocess 
would need an additional separation step (e.g. Filtration or Sedimentation) to remove single 
cells and cell debris from the supernatant. 
Although ensuring a culture free of cell debris, the higher perfusion strategy is not 
suitable from an economical perspective. As previously stated, the number of CMs generated 
per liter of culture medium throughput (CMs/L) can be used to measure the cost-
effectiveness of a stem cell bioprocess. At the end of the bioprocess with the higher perfusion 
strategy, 1.7x108 CMs/L were obtained, whereas with a lower perfusion strategy achieved 
3.8x108 CMs/L. Five times more medium was used in the high perfusion strategy during CM 
selection, resulting in higher overall costs of the bioprocess when compared to the lower 
perfusion strategy. The values obtained are lower than the highest result stated in the 
literature for CM production using perfusion-based strategies, 5.1x108 CMs/L [99], which 
reflects the high quantity of medium used in these experiments. 
 In this work, an automated continuous perfusion strategy was implemented in the 
bioprocessing of miPSCs. This implementation is a step towards obtaining a fully automated 
and integrated bioprocess, capable of generating miPSC-derived CMs. Also, the perfusion 
strategy developed in this thesis provides a straightforward approach, requiring less culture 
manipulation and with scale-up potential for large-scale production of CMs. In order to obtain 
improved results, a perfusion strategy could also be used during the 
expansion/differentiation phase. During this culture period, cell retention devices (e.g. 
ceramic membrane or spin filters) could be used over computer controlled pumps, aiming to 
enhance cell densities during culture possibly resulting in higher CM productivities. 
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4.1.3  Structural and functional characterization of miPSC-derived CMs  
 At the end of the bioprocess it is essential to confirm the quality (phenotype, potency 
and functionality) of the final differentiated product. Cardiospheres obtained from Stirred 
Tank and Wave 1L BRs were dissociated, plated into 2D static plates and cultured for a few 
additional days. CMs were characterized based on their structural features using 
immunocytochemistry tools. 
 
Figure 4.7: Structural characterization of miPSC-derived CMs produced in Stirred Tank and 
Wave BRs. CM aggregates were dissociated into single cells, plated on 2D plates and cultured for 
additional days before analyses. Immunofluorescence labeling of CMs (from both bioreactor systems) 
using sarcomeric α-actinin, titin and troponin I antibodies (red). Expression of eGFP was also detected 
on differentiated CMs (green). Nuclei were labeled with Hoescht 33432 (blue). Scale bars: 50 μm.  
 Figure 4.7 shows that CMs produced in both bioreactor systems exhibited a typical 
cardiac morphology, with highly organized α-actinin, titin and cardiac troponin I structures, 
while still expressing eGFP. CMs were also characterized based on their functional properties 
using cellular electrophysiology. 
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Figure 4.8: Functional characterization of miPSC-derived CMs produced in Stirred Tank and 
Wave BRs. CM aggregates were dissociated into single cells, plated on 2D plates and cultured for 
additional days before analyses. A) Immunofluorescence labeling of CMs (from both bioreactor 
systems) using atrial natriuretic peptide (ANP) antibody (red). Nuclei were labeled with Hoescht 
33432 (blue). Scale bars: 50 μm. B) Percentage of each CM subtype (Atrial, Ventricular and Pacemaker) 
in the final differentiated population from both bioreactors. C-E) Pharmacological response of CMs. C) 
Effects of 1 µM Isoproterenol (Iso) on beating frequency and on action potential duration at 90% 
repolarization (APD90) in miPSC-derived CMs. D) Effects of 1 µM Carbachol (Cch) on beating 
frequency and on action potential duration at 90% repolarization in miPSC-derived CMs. E) 
Representative recording of wave-derived CM action potentials. APs were recorded before the 
application of the drug (Control) in the presence of the drug (Iso/Cch), and after washout of the drug 
(washout). F) Graphical representation of calcium level cycling contractions determined by confocal 
imaging of the calcium dependent dye Rhod-3. Three independent cells were analyzed (CM #1-3). 
Significantly different results: P<0.05 (*) and P<0.01 (**) vs control.  
 Action potential (AP) recording on single CMs was performed by our collaboration at 
University of Cologne (UKK). The results are presented in Figures 4.8B-E and Table 4.2. APs 
are generated as a result of opening and closing of voltage-gated ion channels in the 
sarcolemmal membrane. APs occur when positively charged ions (i.e. K+, Na+, Ca2+) diffuse 
through the cells membrane, inducing changes in membrane potential. These diffusions cause 
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membrane depolarization and repolarization. The frequency is a direct measurement of 
action potentials, as higher frequencies results in more action potentials occurring.  
 The results show that CMs from both bioprocesses exhibited mainly an atrial-like 
phenotype.  Figure 4.8A shows that most CMs presented cytoplasmic (ANP)-granules, a 
peptide that is synthesized and stored by atrial-like CMs [41]. The APs characteristic of atrial-
like phenotype can be identified by the absence of a distinct plateau during the repolarization 
phase [82] (Figure 4.8E). These results are in agreement with the ones obtained in RT-PCR 
analysis, which showed a reduced expression of HCN4 and Myl2 markers (characteristic of 
pacemaker and ventricular-like phenotypes, respectively) in the final differentiated 
population (Figure 4.5A/C, Page 41), when compared to the Myl7 marker (atrial-like 
phenotype). These results were expected due to the use of the α-MHC promoter that becomes 
restricted to atrial regions throughout early fetal development [146].  
Table 4.2: Action potential parameters for CMs obtained from Stirred Tank and Wave BRs.  
MDP - Maximum Diastolic Potential; Vmax – maximum velocity of depolarization; Vdd – velocity of 
diastolic depolarization; APD90 – action potential duration at 90% repolarization; APD50 - action 
potential duration at 90% repolarization.  
Bioreactor Stirred Tank BR Wave BR 1L 
MDP (mV) -59.81±1.01 -57.97±1.15 
Frequency (beats/min) 321.92±23.27 296.42±25.08 
Vmax (dE/dt) (V/s) 26.52±1.78 20.59±2.38 
Vdd (V/s) 0.10±0.01 0.12±0.01 
APD90  84.40±16.41 83.65±7.29 
APD50* 18.14±1.07 23.01±1.89 
APD90/APD50 5.25±1.27 4.07±0.47 
Cells (n) 22 25 
*Significantly different result: P<0.05 
 According to Table 4.2, AP parameters obtained for CMs derived from both 
bioreactors were very similar, presenting no statistical difference (except ADP50), showing 
that CMs produced in both developed strategies present similar functional properties. In 
addition, the obtained results were in agreement with the values described in literature for 
atrial-like CMs derived from murine ESCs and iPSCs [136]. Moreover, the produced CMs 
exhibited AP parameters similar to the ones described for atrial-like late development stage 
(LDS) fetal CMs (differentiation day 16-19), such as MDP (-63.3±1.3 mV), Frequency (234±19 
beats/min), Vmax (27.9±0.7 V/s) and Vdd (0.115±0.017 V/s) [136]. In addition, the response 
of miPSC-derived CMs to β-adrenergic regulation with Isoproterenol and muscarinic 
signaling with Carcachol were tested. When 1µM of Isoproterenol, a vasodilator that 
increases heart rate [147], was administered to CMs, significant increase of AP frequency was 
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observed (Figure 4.8C/E). Also, the increase in frequency resulted in rapid membrane 
repolarization and lower AP duration, hence lower APD90 (Figure 4.8C). Positive 
chronotropic effects of Isoproterenol were reversible on washout. When administering 1µM 
of Carbachol, a synthetic acetylcholine analog known to decrease heart rate [148], a decrease 
in AP frequency was expected. However, an absence of AP was observed (Figure 4.8D-E). This 
effect could possibly be justified by the use of an excessive dose/concentration of Carbachol 
that could completely restrain ion diffusion through the cells membrane. Lower 
concentrations of Carbachol should be tested to verify this hypothesis. Also, it should be 
noted that positive chronotropic effects of Carbachol were reversible on washout. 
 To establish that calcium signaling drives excitation-contraction coupling of miPSC-
derived CMs, changes in intracellular calcium were imaged across the contraction cycle using 
confocal microscopy. CMs exhibited a synchronized calcium transient profile (Figure 4.8F). 
Also, as expected, calcium traces accompanied contraction of the cells, indicating normal 
calcium homeostasis (results not shown). 
 In summary, CMs obtained at the end of both bioprocesses present molecular, 
structural and functional properties typical of CMs, as proved by immunocytochemistry and 
electrophysiology analysis. 
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4.2 Cryopreservation and hypothermic storage of miPSC-derived CMs 
 The bioprocesses developed in this thesis, using fully controlled Stirred Tank and 
Wave BRs, were able to produce quality miPSC-derived CMs. Cryopreservation of CMs is a 
critical step in integrated bioprocesses. Thus, efficient long term storage of these cells is 
needed, without compromising their viability and/or functionality. Cryopreserving CMs 
allows the generation of master and working cells banks, which is a prerequisite for clinical 
or industrial applications, where quality and consistent stocks of cells are a demand. In 
addition, suitable hypothermic storage is also needed for appropriate transport of bioprocess 
developed CMs, avoiding the need of cryopreservation during short term delivery of these 
cells. 
 This task aimed at developing efficient protocols for cryopreservation and 
hypothermic storage of miPSC-derived CMs. This approach consisted on designing 2D and 3D 
cryopreservation procedures, using different cryopreservation medium formulations: 
FBS+10% DMSO, CryostorTMCS10 and PRIME-XV (solution still not commercially available). 
FBS+10% DMSO is a common formulation used in cryopreservation strategies. Previous data 
from our lab has shown that cryopreservation with this formulation is capable of suitable 
post thaw recovery, using neuroblastoma N2a and colon adenocarcinoma Caco-2 cell lines 
[149]. This formulation has also been used with ESC-derived CMs, however low cell survival 
was observed [150]. CryoStorTMCS10 (CS10) is an animal protein-free, serum-free and 
defined cryopreservation medium containing 10% (DMSO). This solution has been shown to 
effectively cryopreserved ESC-derived CMs as single cells [151]. PRIME-XV is a new variant of 
Irvine Scientific cryopreservation solutions, with the feature of being DMSO-free (according 
to manufacturer’s information). Hypothermic storage, at 4°C, was also tested using 2D and 3D 
approaches. For this purpose, a commercial solution was tested, HypoThermosol®-FRS 
(referred to as HTS from now on), which is a serum-, protein- and DMSO-free solution that 
enables improved and extended preservation of cells.  
 During the last few years, different serum-containing medium formulations have been 
tested for the cryopreservation of stem cells. However, despite being economically appealing, 
most of the used serums contain undefined proteins and show batch-batch variation which 
ultimately lead to unpredictable cell survival. Recently, the use of Rho-associated kinase 
inhibitor (ROCKi) has been reported to improve cell viability after thawing, in both human 
ESCs [152] and human ESC-derived CMs [150]. Thus, the effect of pretreatment with ROCK 
inhibitor on CM viability after thawing was also evaluated, using the FBS + 10% DMSO 
formulation. 
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4.2.1  Cryopreservation of CMs as monolayers and aggregates 
 miPSC-derived CMs were cryopreserved as confluent 2D monolayers. As previously 
indicated cells were plated at 1x106cell/well, maintained for 7 days and cryopreserved in the 
tested cryopreservation solutions (Materials and Methods 3.3.1). After thawing at 37°C, CM 
post-thaw recovery was evaluated during a 7 day period. Figure 4.9 presents the main results 
obtained from post-thaw evaluation of CMs. 
 
Figure 4.9: Effect of cryopreservation medium on miPSC-derived CM viability after 
cryopreservation of CM monolayers. Different cryopreservation medium formulations were tested: 
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FBS+10%DMSO (with and without ROCK inhibitor pretreatment), CryoStorTMCS10 and PRIME-XV. 
Post-thaw recovery of CMs was evaluated during 7 days. A) Cell viability was assessed using FDA (live 
cells, green) and PI (dead cells, red) at days 0 and 7. B) Phase contrast and fluorescence imaging 
showing eGFP positive cells (green) at day 3. Scale bars: 200μm. C) Evaluation of metabolic activity 
recovery during the 7-day post-thaw evaluation period. D) Cumulative values of LDH release during 
post-thaw evaluation period. Significantly different results: P<0.01 (**); CS10 and FBS+DMSO w/ 
ROCKi vs FBS+DMSO w/o ROCKi and PRIME-XV. 
 The results obtained show that CS10 and FBS+10% DMSO, with ROCK inhibitor 
pretreatment (FBS+DMSO w/ ROCKi), were suitable solutions for miPSC-derived CM 
cryopreservation as 2D monolayers. Most of the CM monolayer remained viable and 
maintained eGFP expression immediately after thawing and during the 7-day post-thaw 
evaluation period (Figure 4.9A-B). In addition, beating CMs were observed 1-2 days after 
thawing (results not shown). On the other hand, FBS+10% DMSO, without ROCK inhibitor 
pretreatment (FBS+DMSO w/o ROCKi), and PRIME-XV proved to be unsuitable for the 
cryopreservation of CM monolayers, as extensive cell death was observed immediately after 
cell thawing (Figure 4.9A). These fluorescence imaging results are in line with the ones 
obtained with the PrestoBlue assay (Figure 4.9C). CS10 and FBS+DMSO w/ ROCKi show 
significant differences in metabolic activity recovery over FBS+DMSO w/o ROCKi and PRIME-
XV, presenting recoveries over 87% and 94% (respectively) during the 7-day evaluation 
period. No significant differences in metabolic activity recovery were observed between CS10 
and FBS+DMSO w/ ROCKi. At day 7, both solutions presented a 100% metabolic activity 
recovery. Also, a significant increase in cell viability and metabolic activity recoveries was 
observed when cells were pretreated with ROCKi, using the FBS+DMSO formulation (Figure 
4.9A/C). In fact, very low metabolic activity recoveries were obtained when cryopreserving 
CMs with FBS+DMSO w/o ROCKi and PRIME-XV solutions (<2% at day 7) (Figure 4.9C). In 
addition, cryopreservation using PRIME-XV resulted in increased LDH release during post-
thaw recovery, presenting a 1.5-fold and 1.8-fold increase over CS10 and FBS+DMSO w/ 
ROCKi (respectively) at day 1 (Figure 4.9D). 
 
 CM applications in research and therapy would greatly benefit from the development 
of 3D based cryopreservation procedures as cardiospheres express a tissue-like structure, 
more resembling of the in-vivo environment that enhances cell functionality. Efficient 
cryopreservation of cardiospheres would present a step forward towards the application of 
these cells, as 3D aggregates can be useful tools in drug screening, toxicology studies and 
regenerative medicine applications (reviewed in [153]). As previously described, 
cardiospheres were transferred to cryovials at 300 aggregate/vial and cryopreserved in the 
various cryopreservation solutions (Materials and Methods 3.3.2). After thawing, 
cardiospheres were transferred to well plates and cultured in static conditions for 7 days. 
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Post-thaw recovery was evaluated during time period. Figure 4.10 presents the main results 
obtained from post-thaw evaluation of cardiospheres.  
 
Figure 4.10: Effect of cryopreservation medium on miPSC-derived CM viability after 
cryopreservation of cardiospheres. Different cryopreservation medium formulations were tested: 
FBS+10%DMSO (with and without ROCK inhibitor pretreatment), CryoStorTMCS10 and PRIME-XV. 
Post-thaw recovery of CMs was evaluated during 7 days. A) Cell viability was assessed using FDA (live 
cells, green) and PI (dead cells, red) at days 0 and 7. B) Phase contrast and fluorescence imaging 
showing eGFP positive cells (green) at day 3. Scale bars: 200μm. C) Evaluation of metabolic activity 
recovery during the 7-day post-thaw evaluation period. Significantly different results: P<0.05 (*) 
P<0.01 (**) vs FBS+DMSO w/o ROCKi.  
 The results obtained show that CS10 and FBS+DMSO w/ ROCKi, were the best 
solutions for cryopreservation of CMs cultured as cardiospheres. Immediately after thawing, 
high cardiosphere viability was observed using these solutions (Figure 4.10A). In addition, 
beating of cardiospheres was observed 2-3 days after thawing (results not shown). However, 
during the 7-day post-thaw evaluation period, some cell death was observed. Nonetheless, 
some cardiospheres were able to fully maintain their viability, when using CS10 (Figure 
4.10A; day 7). Despite some apparent cell death, cardiospheres still showed considerable 
eGFP expression after cryopreservation using these solutions (Figure 4.10B). Similar to the 
results observed in monolayer cryopreservation, FBS+DMSO w/o ROCKi and PRIME-XV were 
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inappropriate for cardiosphere cryopreservation. Cryopreservation using these solutions 
resulted in extensive cell death after thawing (Figure 4.10A) and consequent no eGFP 
expression (results not shown). 
 Figure 4.10C shows the metabolic activity recovery of cardiospheres.  Cardiospheres 
cryopreserved with CS10 and FBS+DMSO w/ ROCKi presented the highest recoveries 
achieving values of 94% and 91% at day 0, respectively. The decrease in cell viability 
observed in Figure 4.10A was in line with a decrease in metabolic activity recovery, as a 27% 
(CS10) and 38% (FBS+DMSO w/ ROCKi) decrease in metabolic activity recovery was 
observed by day 7. On the other hand, cryopreservation of CMs using FBS+DMSO w/o ROCKi 
and PRIME-XV, show reduced metabolic activity recoveries during the post-thaw period. In 
addition, FBS+DMSO w/o ROCKi presented an initial value of 30%, which reduced to 9% at 
day 7. It should be noted that a significant difference in metabolic activity recovery is 
observed at the end of the 7-day recovery period, as the results obtained with FBS+DMSO w/ 
ROCKi present an increase of 45% in metabolic activity recovery over the ones obtained with 
FBS+DMSO w/o ROCKi (Figure 4.10C) 
 
 The results obtained from cryopreservation of miPSC-derived CMs as monolayers and 
cardiospheres showed that CS10 and FBS+DMSO w/ ROCKi were the most suitable solutions 
for the strategies evaluated in this work. CS10 is supplemented with components to reduce 
generation of free radicals or energy deprivation during cryopreservation and inhibit 
apoptosis [154]. The improvement in cell survival is related to a direct reduction in the level 
of both apoptosis and necrosis by inhibition of cellular stress during cryopreservation [154, 
155]. In addition, CS10 contains 10% DMSO which is a penetrating cryoprotectant agent 
(CPA). Penetrating CPAs have been suggest to act by reducing the concentration of damaging 
electrolytes at a given subzero temperature [156] and reducing the extent of cell volume 
change during slow-rate freezing and thawing [157]. On the other hand, PRIME-XV had no 
DMSO addition (according to manufacturer’s information) which could help justify the 
extended cell death observed in these experiments. However, it should be noted that no 
information regarding the added CPA and concentration of CPA used in this solution is 
known. Although these solutions presented the most promising results, some qualitative 
differences were observed when comparing the results obtained from post-thaw evaluation 
of monolayers and cardiospheres. The slight decrease in cell viability and metabolic activity 
recoveries observed in cardiospheres could be related to heat and mass diffusion restrictions 
in cardiospheres [158], which could eventually restrict the diffusion of CPAs to the center of 
the aggregate. Also, ice crystals can intercalate the tissue and mechanically deform cells, and 
intracellular ice may be formed between the intercellular interactions needed to maintain the 
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functional 3D architecture [158]. In a future perspective, it could be interesting to evaluate 
the impact of the size and shape of cardiospheres on the results obtained. 
 The ROCK inhibitor pretreatment on the FBS+DMSO formulation showed promising 
results. An improvement of 100% (CM monolayers) and 44% (cardiospheres) on metabolic 
activity recovery was observed when ROCK inhibitor pretreatment was performed using this 
medium formulation. Previous work has stated that ROCK inhibitor enhances cell–cell 
adhesion and cell aggregation by modulating gap junctions, thereby blocking the pathway to 
apoptosis (reviewed in [159]). In addition, the improvement observed with ROCK inhibitor 
pretreatment may also be related to the ability to avoid anoikis, which is a subtype of 
apoptosis induced by the loss of cell adhesion, e.g. the loss of anchorage to the extracellular 
matrix, as adhesion to the extracellular matrix been shown to prevent caspase activity, thus 
preventing apoptosis [160]. Despite the improvement observed in cell recovery yields and 
viability with ROCK inhibitor pretreatment, some difference weas observed when comparing 
the results obtained from 2D and 3D cryopreservation using FBS+DMSO w/o ROCKi, as the 
2D approach presented lower metabolic activity recoveries. The presence of cell–cell and 
cell–surface interactions on monolayers has been shown to render cells more susceptible to 
freezing injury [161, 162]. These interactions are likely sites for monolayer damage by the 
osmotic stresses and phase changes in cryopreservation, and have been associated with 
enhanced susceptibility to intracellular ice formation [163]. The cells extended morphology 
may also create conditions for cryopreservation-induced damage to the cells structure 
(cytoskeleton or gap junctions) due to mechanical forces, such as extracellular ice [161]. 
DMSO was the only compound added to prevent cryopreservation damage unlike CS10, 
which contains numerous high quality cryo-protecting components. These features may 
explain the difference observed between cryopreservation of monolayers and cardiospheres 
using this solution. Despite this fact, from an economical perspective, the FBS+DMSO 
formulation is less costly and easy to prepare in any stem cell lab, as most of its components 
exist for common lab procedures.  
 Cryopreservation has already been accomplished successfully with some cells such as 
human PSCs (ESCs and iPSCs) [164], neuronal cells [165] and Caco-2 cells  [149], using single 
cell, 2D or 3D approaches. CMs derived from ESCs have been cryopreserved, using single cell 
approaches [150, 151]. The results obtained in this work show, for the first time, the 
successful cryopreservation of miPSC-derived CMs using both monolayer and cardiosphere 
approaches. 
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4.2.2  Hypothermic storage of CMs as monolayers and aggregates 
 CMs were also stored at hypothermic temperatures with the aim of developing 
efficient procedures for short-term transport/shipping. CMs were stored as monolayers 
(1x106cell/well) and cardiospheres (300 aggregates/vial) at 4°C for 7 days. After the storage 
period, cell recovery was evaluated for 7 days. Figure 4.11 presents the main results obtained 
from hypothermic storage of CMs. 
 
Figure 4.11: Hypothermic storage of miPSC-derived CMs as monolayers and cardiospheres. 
Hypothermic storage was tested using HTS as a storage solution. Cell recovery was evaluated for 7 
days. A) Cell viability was assessed using FDA (live cells, green) and PI (dead cells, red) after cell 
recovery. B) Phase contrast and fluorescence imaging showing eGFP positive cells (green) at day 1. 
Scale bars: 200μm. C) Evaluation of metabolic activity recovery during 7 days after storage.  
 The results obtained show that HTS is a suitable solution for hypothermic storage of 
CMs cultured as 2D monolayers and 3D cardiospheres, during a 7-day storage period. CM 
monolayers and cardiospheres remained viable after storage (Figure 4.11A) and maintained 
eGFP expression in both approaches (Figure 4.11B). Also, beating of CMs as monolayers and 
cardiospheres was observed immediately after storage recovery (results not shown). 
Metabolic activity recovery results show an increase in metabolic activity until day 7 (Figure 
4.11C). The reduced metabolic activity observed at day 0 is a result of storage at hypothermic 
temperatures using HTS, which reduces cell metabolism during storage [166]. Together with 
CS10, both solutions are part of a number of preservation solutions currently available in the 
field of regenerative medicine [167]. These solutions have been carefully formulated to 
maintain the ionic and hydraulic balances of cells at low temperatures. This feature facilitates 
preservation of cell homeostasis and control of ionic environment, not achievable using 
traditional preservation formulations consisting of basal culture medium with serum protein 
and DMSO supplementation [167]. This solution has been tested using mesenchymal stem 
cells, achieving cell recoveries of 85% after 4 days storage at hypothermic temperature [168]. 
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Previous studies have shown the successful hypothermic storage of neonatal CMs, during a 2-
day storage period [169]. However, no previous studies have been shown regarding 
hypothermic storage of miPSC-derived CMs. 
4.2.3  Characterization of cryopreserved and hypothermically stored CM 
monolayers 
 To confirm CM quality after cryopreserved and hypothermic storage, CM monolayers 
were characterized based on their structure. For this analysis, CM monolayers cryopreserved 
using CS10 and stored in hypothermal conditions using HTS were used. Figure 4.12 presents 
the structural characterization of these cells using immunocytochemistry. 
 
Figure 4.12: Structural characterization of cryopreserved and hypothermically stored CM 
monolayers. Immunofluorescence labeling of CM monolayers, obtained at day 7 of the post-thaw 
recovery period, using sarcomeric α-actinin, titin and troponin I antibodies (red). Expression of eGFP 
was also detected on cryopreserved and stored CMs. Nuclei were labeled with Hoescht 33432 (blue). 
Scale bars: 50 μm.  
 Immunocytochemistry was performed to confirm the quality, detecting the presence 
of cardiac-specific proteins, on cryopreserved and stored CMs. Figure 4.12 shows that CMs 
cryopreserved in CS10 and hypotermically stored exhibited a typical cardiac morphology, 
with highly organized α-actinin, titin and cardiac troponin I structures, while still expressing 
eGFP. These results confirm that cryopreserved CMs, using CS10 solution, and hypothermic 
storage using HTS maintained their structural features. This confirms that the preserved CMs 
maintained their structural quality and ultimately proves that the strategies developed in this 
thesis efficiently cryopreserved and stored miPSC-derived CMs.  
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4.3 Evaluation of the potential of miPSC-derived CMs to be used in the 
development of cardioprotective cell-based assays 
 CMs derived from PSCs have been used for various toxicology applications, such as 
drug screening assays or cardiotoxicity screening [170]. This task aimed at evaluating the 
potential of miPSC-derived CMs to be used in the development of cardioprotective strategies. 
For this purpose, CMs were evaluated as monolayers and cardiospheres. On a preliminary 
approach, CM monolayers were exposed to 50-900µM H2O2 for 20 hours. Figure 4.13 
presents the results from this experiment. 
 
Figure 4.13: Effect of oxidative stress and antioxidant pretreatment on CMs. H2O2 oxidative stress 
was induced exposing cells to concentrations between 50-900µM, during 20 hours. For 
cardioprotective effect evaluation, Cells were treated before H2O2 exposure with 150 and 300mg/L of 
catechin, during 24 hours. Cell viability was measured before and after oxidative stress. A) Evaluation 
of oxidative stress on cell viability. CM monolayers and cardiospheres were tested. B) Cardioprotective 
effect of catechin during oxidative stress, using CM monolayers, when exposed to 400μM and 500μM 
H2O2.. Significantly different results: P<0.01 (**) vs Control w/ H2O2.  
 The preliminary results obtained from the monolayer approach show a decrease in 
cell viability when CMs were exposed to concentrations higher than 150µM H2O2 (Figure 
4.13A). To evaluate the cardioprotective effect of an antioxidant compound, IC50 and IC80 of 
H2O2 were estimated. These measures are commonly used to determine the concentration of 
an inhibitor where the viability is reduced by 50 and 80%, respectively. The results show that 
IC50 and IC80 presented values of approximately 400 and 500µM, respectively. These 
concentrations were chosen and used to evaluate the cardioprotective effect of catechin, an 
antioxidant compound already reported to show cardioprotective effect on rat heart cell lines 
[171]. With this objective, CM monolayers were pretreated with different concentrations of 
catechin for 24 hours – 150 and 300mg/L, before exposure to H2O2. The results obtained 
show that catechin pretreatment resulted in a significant increase in cell viability when 
compared to untreated cells subjected to oxidative stress (Figure 4.13B). In addition, 
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pretreatment with 300mg/L proved to be the most promising concentration for this natural 
compound, as an increase of 31% (400μM H2O2) and 39% (500μM H2O2) in CM viability was 
observed when compared to the viability of untreated CMs. These results show that catechin 
was able to protect CMs against cellular damage from oxidative stress induction, in a dose 
dependent manner. 
 The cardiotoxicity of H2O2 was also evaluated on CMs cultured as 3D cardiospheres.  
The results obtained show that cardiospheres display inherent higher resistance to H2O2 
when compared to CMs cultured as monolayers (Figure 4.13A). As a consequence, estimated 
values of IC50 and IC80 increased to 5 and 15mM, respectively. Cell monolayers present 
extended morphologies which makes cell-cell and cell-matrix contacts more exposed to 
oxidative damage. However, cell aggregates contain extensive cell-cell contacts, intercellular 
adhesion structures and well distributed extracellular matrixes [39], allowing them to 
express a tissue-like structure, which may confer more resistance to ROS damage, hence 
explaining the obtained results. 
 According to our knowledge, no previous studies have used miPSC-derived CMs for 
the evaluation of the cardioprotective effect of antioxidant compounds. The preliminary 
results obtained in this work suggest that CMs derived from miPSC are promising tools to be 
used in the establishment of cardiotoxicity and cardioprotective cell-based assays.  Future 
studies should be carried out to evaluate the cardioprotective effect of other compounds, not 
only at the level of cell viability but also on functionality, in both 2D and 3D culturing 
approaches. Also, miPSC-derived CMs should be compared to well established cell model 
systems that have been used for cardiotoxicity evaluation in CMs, including H9C2 [172] and 
AC16 [173] cell lines or adult rat CMs [174]. 
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5. Conclusion 
 In this work, a robust, scalable and integrated strategy for the production and 
selection of miPSC-derived CMs using environmentally controlled bioreactors was developed. 
From the different bioreactor systems tested, the wave bioreactor was the most suitable 
system for CM production, allowing high differentiation yields (60 CM/input of miPSC) and 
CM productivities (16.5x108 CM/L), simultaneously reducing bioprocess duration in 5 days, 
when compared to a stirred tank bioreactor systems. In addition, the wave bioreactor was 
able to produce 2.3x109 CMs which is an adequate quantity of CMs to regenerate an infracted 
area after a heart attack. Extensive characterization revealed that the produced CMs present 
a typical cardiac morphology, structure and functionality. Moreover, an automated 
continuous perfusion system was implemented and integrated in stirred tank bioreactors. 
The perfusion rates tested enabled efficient removal of cell debris and did not compromise 
cardiac differentiation potential and CM yields 
 Furthermore, efficient protocols for the cryopreservation of miPSC-derived CMs as 2D 
monolayers and as 3D aggregates were developed. CryoStorTMCS10 and FBS+10% DMSO 
(with ROCKi pretreatment) revealed to be suitable solutions for cryopreservation of CM-
derived from miPSC, assuring high cell recoveries after thawing. In addition, 
HypoThermosol®-FRS enabled hypothermic storage of CMs for up to 7 days, without 
compromising cell viability, metabolic activity or cardiac morphology. The integration of the 
differentiation and cryopreservation steps herein described constitutes an important 
breakthrough towards the production, banking and shipping of high quality CMs, in a scalable 
and straightforward manner.  
 Finally, it was shown that miPSC-derived CMs present potential to be used in the 
development of cardioprotective cell-based assays. The antioxidant compound catechin, 
which was shown to present cardioprotective effect with other cell lines, was able to protect 
miPSC-derived CMs from oxidative stress induced by H2O2.  
 Hopefully, the robust and integrated bioprocess here developed presents a relevant 
step forward in the transfer of iPSC to clinical and industrial applications. Furthermore, the 
knowledge acquired in this work could be translated to human iPSCs, boosting the 
application of human CMs in various areas, such as regenerative medicine, drug screening or 
cardiotoxicity assays. 
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7. Annexes 
 
Annex 1 - Supplementary table: RT-PCR primers 
Table 7.1: List of primers used for semiquantitative and quantitative RT-PCR analysis. 
Marker For/Rev Sequence 5’-3’ Product lenght 
GAPDH 
for ACCTTGCCCACAGCCTTG 
142 
rev GGCTCATGACCACAGTCCAT 
CTNT 
for GGTGCCACCCAAGATCCCCG 
199 
rev AATACGCTGCTGCTCGGCCC 
NKX2.5 
for CAGCCAAAGACCCTCGGGCG 
142 
rev TGCGCCTGCGAGAAGAGCAC 
HCN4 
For TGCTGTGCATTGGGTATGGA 
337 
rev TTTCGGCAGTTAAAGTTGATG 
MYL2 
for TGCCAAGAAGCGGATAGA 
328 
rev CAGTGACCCTTTGCCCTC 
MYL7 
for AGTAGGAAGGCTGGGACCCG 
306 
rev CTCGGGGTCCGTCCCATTGA 
T-BRACHYURY 
for CTGCGCTTCAAGGAGCTAAC 
91 
rev CCAGGCCTGACACATTTACC 
AFP 
for CCCACTTCCAGCACTGCCTGC 
374 
rev GGCTGCAGCAGCCTGAGAGT 
OCT-4 
for CATGTGTAAGCTGCGGCCC 
268 
rev GCCCTTCTGGCGCCGGTTAC 
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Annex 2 – Adverse effect of different bioreactor designs 
 
Figure 7.1: Bioreactor design adverse effects of miPSC aggregate culture. A) Cell/aggregate 
depostion occured on the sides of the CellbagTM during miPSC culture in the Wave BR. Red arrows 
indicate cell deposition sites. B) Cell/aggregate deposition and excessive foam formation occurred 
during miPSC culture in the PBS BR. Red arrows indicate cell deposition sites. Blue arrows indicate 
excessive foam formation.  
 
 
 
